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Abstract 
An Evaluation of the Role of Conventional and Alternative Discourses on Breast Cancer 
Research Funding Policies  
 Palak Raval-Nelson, MPH 
Robert J.Brulle, Ph.D.  
 
 
 
 
Breast cancer continues to be one of the leading causes of morbidity and mortality 
for women in the United States. It is estimated that every three minutes a woman is 
diagnosed with breast cancer and every twelve minutes a woman dies from this disease.  
Research has identified three potential causes for breast cancer: genetics, lifestyle choices 
and the environment.  Genetics and lifestyle choices contribute to less than 30% of breast 
cancer cases; the remaining 70% of all cases can be linked to the environment and 
environmental carcinogens.  Environmental carcinogens can be found in cosmetics, 
household cleaning materials, and as by products of pollution, such as PCBs and 
organochlorides.  Elimination of environmental carcinogens would lead to prevention. 
Despite this fact, research funding policies tend to neglect the role of environmental 
carcinogens which have been linked to breast cancer and instead fund research for new 
screening and treatment methods.  
In order to determine how and why research funding policies for breast cancer are 
formulated and if in fact these policies systematically exclude funding for the role of 
environmental carcinogens, a thorough analysis of the research funding policies had to be 
conducted.  This study applied theoretical arguments from sociology, elaborated on 
policy theories and utilized the Advocacy Coalition Framework (ACF) and Congressional 
hearings to evaluate how and why research funding priorities for breast cancer are 
determined.  The results of this study revealed that: the discursive coalitions advocating 
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for research into the environmental causes of breast cancer are marginalized during the 
Congressional hearings; due to this marginalization, research funding is limited for the 
environmental coalition; and that the majority of hearing testimony is impacted by the 
economic interests of the presenter.  Since the environmental coalition does not have 
equal participation during the Congressional hearing process, it also does not receive 
equal funding for research activities.   
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 CHAPTER 1: INTRODUCTION 
Overview 
Breast cancer continues to be one of the leading causes of morbidity and mortality 
for women in the United States and around the world (Evans, 2006 p2; Epstein & 
Steinmen, 1997 pp.2-10).  It is estimated that every three minutes a woman is diagnosed 
with breast cancer and every twelve minutes a woman dies from this disease in the 
United States (McCormick, 2003pp.545-549). Since the 1940’s, well over a million 
women have been diagnosed with breast cancer around the world (Evans, 2006).  In the 
United States, breast cancer is the most commonly diagnosed cancer among women and 
approximately 40,000 women lose their lives to this disease annually (Evans, 2006; CDC, 
2006).  In fact, the incident rate for breast cancer has risen dramatically over the past four 
decades (Epstein & Steinmen, 1997; NCI, 2006; ACS, 2006).   
In the United States, well over a billion dollars have been spent during the past 
four decades for breast cancer research (NCI, 2006; Epstein & Steinmen, 1997).  This 
research has identified three potential causes or risk factors which can be associated with 
the development of breast cancer: genetics, individual lifestyle choices, and the 
environment.  (NCI, 2006; Evans, 2006; Epstein & Steinmen, 1997).  The literature 
shows that genetics and lifestyle choices contribute to less than 30% of breast cancer 
cases; while the remaining 70% of all cases can be linked to environmental carcinogens 
(NCI Budget Portfolio, 2005; Breast Cancer Action, 2006).  These carcinogens can be 
present in cosmetics, household cleaning materials, and as by products of pollution, such 
as PCBs and Organochlorides (Epstein & Steinmen, 1997:2-10).  More research into the 
role of these environmental carcinogens as risk factors for breast cancer and elimination 
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of these environmental carcinogens could lead to prevention and reduce the incidence of 
breast cancer (Evans, 2006: 4-10; Epstein & Steinmen, 1997:2-10).   
 
Statement of the Problem 
The federal agency responsible for determining most of the research activists and 
influencing research policies for cancer in the United States is the National Cancer 
Institute (NCI).  NCI’s research priorities fund research activities which are geared 
towards genetics, lifestyle choice, and the development and implementation of new 
screening methods and medical treatments. Research into the role of environmental 
carcinogens receives less then 5 % of the available research funding, despite the fact that 
70% of breast cancer cases can be linked to environmental carcinogens (NCI Budget 
Portfolio, 2005; Breast Cancer Action, 2006).  
In addition to research funds from NCI, over the past decade breast cancer has 
become one of the most publicized forms of cancer.  The “pink ribbon” and the annual 
“Race for the Cure” charity event have become well known symbols for this disease 
(Kolker, 2004:820-844).  Many breast cancer NGOs (Non- Governmental Organizations) 
have been formed and private fundraising activities such as the “Race for the Cure” have 
been initiated to raise awareness and funding for research (Epstein & Steinmen, 1997; 
Moss, 2002).  With increased public and private research dollars available, the incidence 
rates for breast cancer should have declined (CDC, 2006). 
However, the incidence rates for breast cancer have actually doubled from 1 in 14 
women in the 1960s to 1 in 7 women today (Evans, 2006: 3-5).  This higher rate may be 
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attributed to increased screening by physical examination and mammography; however, a 
closer look at the population statistics about the incidence rate reveals that screening does 
not explain the higher rates (Brody, 2005; NCI, 2006).   The high incidence rates of 
breast cancer coupled with the amount of research funding available from both public and 
private sources, raises questions about what research activities are funded and how and 
why research funding policies are determined.   
A review of the literature suggests that there seem to be two main discourses 
which attempt to explain how and why these research policies are determined.  The first 
discourse stems from the NCI and American Cancer Society (ACS).  This discourse 
explains that the research funding policies need to focus research activities around the 
first two risk factors, genetics and lifestyle choices, based on the following reasons: 
• the increase in breast cancer can be attributed to women living longer and 
improved screening methods; 
• medical treatments save lives and prevention techniques are not really 
available;  
• it is difficult to impact the lifestyle choices of women;  
• and it is difficult to study the effects of the environment and conclusively 
pinpoint how the environmental carcinogens cause breast cancer (NCI, 
2006; ACS, 2006).    
The second discourse disagrees with these reasons and explains that the research 
funding policies systematically exclude funding for the role of environmental carcinogens 
because of the following reasons:  
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• the “ruling class” of agencies (the “Cancer Establishment” and “Cancer 
Industry”) which determine the research priorities are led by individuals 
with conflicts of interest; 
• these conflicts of interest include companies which sponsor Breast Cancer 
Awareness month and who also own the chemical companies which 
produce herbicides that are linked to breast cancer incidence (Epstein & 
Steinmen, 1997).   
• powerful corporate actors, such as the pharmaceutical companies, promote 
research funding policies for medical treatment and exclude funding for 
the environmental causes because of  profit; 
• the existing research funding policies for new screening and medical 
treatments are more profitable than mitigation of environmental 
carcinogens which may lead to prevention (Moss, 2002). 
In order to determine how and why research funding policies for breast cancer are 
formulated and if in fact these policies systematically exclude funding for the role of 
environmental carcinogens, a thorough analysis of the research funding policies had to be 
conducted.  This study applied theoretical arguments from sociology, elaborated on 
policy theories and utilized the Advocacy Coalition Framework (ACF) to determine how 
and why research funding priorities for breast cancer are determined.  
The Advocacy Coalition Framework (ACF) provided a mechanism for reviewing 
how competing advocacy coalitions, changes in external subsystems, and a stable system 
of parameters impact policies (Sabatier, 1993).  The competing advocacy coalitions are 
the actors from public and private institutions at varying levels of agencies and 
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government who share belief systems and work to impact the policies to match these 
beliefs.  The external subsystems are the economic and other systems which impact these 
coalitions in their quest to influence the policy process.  The stable system of parameters 
are the rules or the social structures that set the constraints for the policy process 
(Sabatier, 1993).   
 The ACF explains that the policy process involves competition between the 
different stakeholders or advocacy coalitions to establish and maintain the elements of 
public policy; these coalitions unite based on their core beliefs and drive the policy 
process.  The ACF defines an advocacy coalition as a group of “actors” in a policy 
subsystem from a variety of institutions, who share core ideas or beliefs on a particular 
policy issue and they coordinate their actions to form policies based on the core ideas or 
beliefs (Weible, 2005).   These dominant coalitions are not stagnant; they change over 
time and so do the external subsystems and policies (Sabatier, 1993).  
 The ACF has been used in the analysis of air pollution and the formation of air 
quality policies where there were and are strong advocacy coalitions, and market systems 
in place to drive the policies in different directions.  In the case of research funding 
policies for breast cancer the two main discourses described earlier which can be linked 
to six advocacy coalitions consisting of various actors or agencies, who have certain core 
beliefs about what research should be funded.  These six advocacy coalitions for research 
funding are: genetics, lifestyle choices, screening methods, medical treatment, 
environmental carcinogens and prevention.  The conventional discourse emphasizes the 
first four coalitions and the alternative discourse emphasizes the last two.  Also, there are 
external subsystems such as the economic conditions and incident and mortality rates for 
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the disease; and there are the relative stable parameters, such as the Cancer Act and the 
availability of resources. All of these components combine during Congressional 
hearings to drive the policy process and form research funding policies, which determine 
federal appropriations and the national budget.        
Congressional hearings provide a written record of the discussions about issues, 
the actors and agencies involved in these discussions and how they combine to form or 
change policies.  These hearings provide a narrative text of the policy process discussion 
and the key actors who were included or excluded in the discussion to impact the creation 
or change of a policy (Lounbury, 2003:71-104).  By conducting content analysis on 
Congressional hearings and applying the ACF, it was hoped that reasons for how and 
why the policies for research funding are decided will be determined.  
 
Rationale for the Study 
This proposed study will advance the understanding of how and why breast 
cancer research funding policies include or exclude funding for certain risk factors over 
others.  The existing literature points to multiple carcinogens in the environment, as well 
as genetics and life style choices as triggers for causing breast cancer (Evans, 2006; 
Epstein & Steinmen, 1997:2-10).  Despite the existence of this literature, there seems to 
be a disparity in research funding policies; this dissertation aimed to help determine how 
the research funds are being spent and why certain causes receive more research funding 
and other causes are not funded. 
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The Delimitations 
This study proposed to provide an accurate picture of the policy process for breast 
cancer research funding policies and how and why certain causes receive funding over 
other causes.  Two limitations were identified for this study.  Actual Congressional 
hearings which encompass agents or actors can be complicated and often very dynamic. 
Thus, this study is limited by the narrative text provided as a written record of the 
hearings, which does not include the actual visual presentations that may have been 
provided by these agents or actors.    The study was also limited by the reliance on US 
Government Printing Office to provide an accurate, written record of the hearings.  
Assumptions 
For the purposes of this study, the following assumptions were made:  the 
Congressional hearings used in the study were inclusive of breast cancer policy hearings; 
the ACF served as a good framework for this type of analysis; and that the variables 
chosen for study will be adequate. 
Definition of Terms 
 Listed below are the terms and definitions that will be utilized to represent the 
advocacy coalitions for this study: 
Genetics: Defined as the study of heredity; for the purposes of this study, refers 
to the evidence that there are “breast cancer genes” which seem to be responsible 
for contributing to breast cancer: the BRCA1 and the BRCA2 genes (Steingraber, 
2000 & Epstein 2003).   
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Lifestyle Choices: defined as smoking, alcohol consumption, diet, exercise, 
reproductive behavior, and driven by cultural beliefs and social status 
(Steingraber, 2000 & Epstein 2003).   
Screening Methods: Defined as tests and exams used to find breast cancer in 
people who may not have any symptoms; the three methods are breast self-exam, 
clinical breast exam, and mammograms (ACS, 2007).      
Medical Treatments: Defined as medical intervention for a disease; for breast 
cancer, the treatment options can involve removal of the tumor, removal of the 
breast, chemotherapy, radiotherapy, and other medications (ACS, 2007).   
Environmental Carcinogens:  the environment, environmental pollutants and 
carcinogens that are considered as triggers for breast cancer causation (Epstein, 
2003, 2005).  Chemical pollutants produced by industrialization and are not the 
only environmental carcinogens, radiation and everyday items, such as cosmetics, 
pesticides, and household cleaning materials may also cause breast cancer (Brody, 
2005).  
Prevention: though usually associated with early detection and education about 
lifestyle choices; for the purpose of this study, prevention will be defined in 
relation to minimizing exposure to environmental carcinogens (Steingraber, 2000 
& Epstein 2003).   
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CHAPTER 2: LITERATURE REVIEW 
Overview 
 Chapter one introduced information about the breast cancer epidemic and the 
three risk factors associated with this disease.  The chapter also provided the overall 
statement of the problem and the aims of this study, to identify how and why breast 
cancer research funding policies include and exclude funding for certain risk factors.  
This chapter will provide a brief history of this disease; details about the risk factors; the 
two main discourses and the associated six advocacy coalitions that explain how and why 
these research policies are determined; the theoretical framework; and a summary of the 
major findings and gaps. 
 
History & Etiology 
  Human beings have been trying to understand and battle cancer for centuries.  The 
earliest evidence of human cancer dates back to 460-370 B.C showing damage to organs 
and bones from malignant tumors (Diamandopoulus,1996:1595-1602 & Gallucci, 
1985:67-71).  From the beginning, humans have tried to understand what cancer was and 
how it developed.  The notion of cells in the human body forming tumors and attacking 
the body that they dwell in has perplexed society for centuries 
(Diamandopoulus,1996:1595-1602).   
Cancer as defined by the Stedman’s Medical dictionary is the “various types of 
malignant neoplasms, most of which invade the surrounding tissues, may metastasize to 
several sites and invade surrounding tissues… can cause death to the patient…” 
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(Stedman’s, p276).  The actual word cancer comes from the Latin word for crab. 
Basically, cancer is the result of normal cells producing abnormal daughter cells during 
cell division.  These abnormal daughter cells attack nearby tissue and organs and can 
migrate through the body via the bloodstream and lymphatic system to spread the cancer.  
Besides being abnormal, cancer cells reproduce more rapidly than normal cells and as 
time goes on these abnormal cells form malignant tumors or cancer (National Cancer 
Institute, 2000). 
 In the case of breast cancer, the disease begins when cells in the breast tissue 
called lobes and ducts begin to multiply abnormally and form tumors.  The breast 
consists of glands called lobules which produce breast milk, small tubes called ducts that 
connect the lobules to the nipple, both fatty and connective tissue, blood vessels, and 
lymph vessels. Lymph vessels are similar to veins that carry lymph fluid which contains 
immune cells and other fluids. These vessels are distinct of the tissue that forms the 
lymph nodes. These nodes extend into the arm pit area and are called axillary nodes 
(ACS, 2006).   
 Most lumps in the breast tend to be benign breast tumors which do not spread 
throughout the body. Simple removal of the benign tumor is required. If however, the 
tumor is malignant it can spread locally or the cancer can spread through the lymph nodes 
and the bloodstream to the rest of the body (Anatomy of the Breast, 2003).  A graphical 
description of how and where breast cancer develops is provided on the next page (ACS, 
2006). 
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Figure P-1: Diagram of Breast: “A woman’s breast is made up of glands that make breast milk 
(lobules), ducts (small tubes that carry milk from the lobules to the nipple), fatty and connective tissue, 
blood vessels, and lymph (pronounced limf) vessels. Most breast cancers begin in the cells that line the 
ducts (ductal cancer), some begin in the lobules (lobular cancer), and the rest in other tissues. Lymph 
vessels are like veins, except that they carry lymph fluid instead of blood. Lymph is a clear fluid that 
contains immune system cells and waste products. Most lymph vessels lead to small, bean-shaped 
collections of tissue called lymph nodes. Most lymph vessels of the breast lead to lymph nodes under the 
arm. These are called axillary (ax-uh-lair-ee) nodes. If breast cancer cells reach the underarm lymph nodes 
and continue to grow, they cause the nodes to swell. Once cancer cells have reached these nodes they are 
more likely to spread to other organs of the body as well.” (ACS, 2006: 
http://www.cancer.org/docroot/CRI/content). 
 
The history of the various types of cancer varies based on incidence of that particular 
type and the percentage of population affected.  The first documented case of breast 
cancer in the world can be traced back to 1600 BC (Diamandopoulus,1996:1595-1602 & 
Gallucci, 1985:67-71).  In the United States breast cancer and formal treatment can be 
traced back to 1890, when the American surgeon William Halstead developed the radical 
mastectomy (Plotkin, 1996: 53-82). This surgical procedure involved a complete removal 
of the tumor and everything around it including the chest-wall muscles and lymph nodes.  
The goal of this surgical procedure was to remove the tumor to eliminate the spread of 
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the cancer.  Often, however, this procedure left women horribly disfigured and 
sometimes considered to be outcasts of society (Plotkin, 1996: 53-82).     
This procedure of surgically removing the tumor made the assumption that the 
cancer spread slowly and steadily from one site to the rest of the body and that removal 
of the tumor was sufficient (Plotkin, 1996: 53-82).  It did not explain how and why the 
cancer reoccurred or spread to other areas of the body.  It was not until surgeons and 
radiologists began working together to better understand how breast cancer spread, with 
the hope that this cancer could be controlled, that the concept of early detection through 
X-rays or what is now known as mammography was conceived (Love & Barsky, 
1996:171-175).   
In the early 1930’s this idea of trying to control the breast cancer through early 
detection and the negative implications of the radical mastectomy lead the medical 
community to develop medical treatments that were less invasive and screening methods 
for breast cancer with the hope that the disease would be found before it spread to other 
organ systems in the body (Love & Barsky, 1996:171-175).  Self breast exams and 
mammograms were developed later as a result of this earlier work (ACS, 2004). 
Also during this time, the United States government and its political leaders began to 
realize the potential catastrophic effects of cancer on the American people and passed the 
National Cancer Act creating the National Cancer Institute (NCI).  This new government 
agency complimented the American Cancer Society (ASC), an NGO which was 
originally formed in 1913 in New York City (Glazer, 1997:1-40).  These agencies and the 
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medical community began significant research activities to find treatments and a cure for 
cancer in the 1960’s (ACS, 2004).   
The NCI was empowered further through amendments to the National Cancer Act, 
and the ACS was empowered through increased publicity and funding.  The medical 
community also continued the quest for better treatment options including chemotherapy, 
radiation and tumor or organ removal as the last resort.  Funding for research into new 
medical treatments and finding a cure for breast cancer increased over time (Glazer, 
1997:1-40).  As the rates of breast cancer continued to rise, the Breast Cancer Act of 
1990 and new NGOs were formed and commissioned to raise awareness and private 
funding to conduct research for a cure (McCormick, 2003:545-576).    
As these NGOs spent their time emphasizing the need for treatment and cure for 
breast cancer, women began to organize around defining the causes of breast cancer.  One 
of these women was 68-year-old Charlotte Haley.  Ms. Haley had begun making peach 
ribbons in her home and distributing these ribbons to raise awareness because her 
daughter, sister and grandmother all had breast cancer. She realized the need for research 
activities which focused specifically on determining a cause for this disease and the 
possible prevention activities necessary to control this disease.  She distributed thousands 
of peach ribbons in her home town at stores with cards that read: "The National Cancer 
Institute’s annual budget is $1.8 billion, only 5 percent goes to cancer prevention through 
the elimination of environmental carcinogens. Help us wake up our legislators and 
America by wearing this ribbon." (Breast Cancer Action, 2006).   
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At the same time that she was successfully raising awareness with her ribbon, a need 
for a national logo for breast cancer had surfaced.  The information about Ms.Hailey’s 
ribbons reached the executives from Estée Lauder and Self magazine and they stepped in 
and asked her if they could use her ribbon. Even though Ms. Haley refused, these two 
corporations consulted their attorneys and came up with the pink ribbon.  Of course, 
Haley’s ribbon was no longer valuable and the pink ribbon became the commercialized 
symbol for breast cancer (Breast Cancer Action, 2000).  
Causes & Risk Factors 
Though the exact causes of breast cancer have not yet been determined, the 
majority of literature and research point to three potential causes: genetics, individual 
lifestyle choices, and the environment (Steingraber, 2000; Epstein, 2003; Davis, 
2002:159-192).  There is a body of literature to support the need for additional research 
funding to conduct research activities which target each of these three causes (NCI, 
2006).  A brief explanation of each of these causes will now be provided.  
Genetics 
Breast cancer research activities have collected data about the role of DNA and 
genetic mutations that are passed down from one generation to the next that may lead to 
breast cancer in the offspring (NCI, 1995).  There is evidence that there are “breast 
cancer genes” which seem to be responsible for causing breast cancer: the BRCA1 and 
the BRCA2 genes.  These genes are mutated from normal cells and are inherited by 
offspring and can potentially cause breast cancer in the individual who inherits the 
mutated genes (Anatomy of the Breast, 2003).  One of the medical treatments that can 
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help women who have the BRCA1 mutation is to have their ovaries surgically removed 
before age 40.  This procedure seems to reduce the risk of breast cancer (ACS, 2006). 
Another medical treatment involves the drug tamoxifen.  Though the research is still 
ongoing, some studies have shown that women who have a higher risk for breast cancer 
may not get the disease if they take this medication. Raloxifene, another medical drug 
that is being tested to see if it reduces breast cancer risk (ACS, 2006) 
 Though the BRCA 1 and BRCA2 genes have been identified as potential triggers 
for breast cancer, the literature suggests that more research needs to be conducted to 
establish a conclusive link (Brody, 2005).  There is only a weak link between heredity 
and breast cancer and there is evidence that the majority of breast cancer occurs without 
specific genetic causes (Vogelstein, 1995).  Only 5 to 10 percent of cases can be linked to 
genetics, the remaining 90 to 95 percent of breast cancer cases do not have a conclusive 
hereditary connection (Colditz, 1993: 338-343).   
Research has suggested that the breast cancer genes may be a result of genetic 
mutations which may have been caused by exposures to environmental carcinogens.  
DNA mutations are generally caused by exposure to certain environmental carcinogens; 
this mutated DNA can be passed down from parent to child causing the child to become 
more sensitive to certain environmental carcinogens (Holzman, 1996:951).  For example, 
the mutated DNA that is passed down to the child in the case of 5 to 10 percent of 
heredity related breast cancer cases may be responsible for the abnormal cell division 
causing tumor formation in the breast (Steingraber, 2000).  The exposure to 
environmental carcinogens, which may produce mutated DNA and “cancer genes” can be 
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passed down to the child from parent (Steingraber, 2000).  Endocrine disruptors are one 
example of how exposure to environmental carcinogens can cause genetic defects 
(Solomon, 2002:147-162). Endocrine disruptors are the hazardous chemicals that work 
by binding to or blocking hormone receptors and can lead to genetic mutations 
(Steingraber, 2000).  Understanding the effects of exposures to environmental 
carcinogens and endocrine disruptors may assist in mitigating and eliminating the 
carcinogens present in the environment and prevent breast cancer; not much can be done 
to change the current genetic material that an individual inherited (Steingraber, 2000).   
Lifestyle Choices 
Research activities also focus on the impacts of individual lifestyle choices and 
how these choices may cause an individual to acquire breast cancer.  Many public health 
education campaigns have been developed to promote healthier lifestyle choices (Evans, 
2006).   Both the NCI and the ACS spend a large portion of their research funding on 
educating and promoting “better lifestyle choices” (ACS, 2006; NCI, 2006).  There are a 
multitude of media messages and health education literature which associate individual 
lifestyle choices to breast cancer.   
Lifestyle choices encompass: smoking, alcohol consumption, diet, exercise, 
reproductive behavior, and cultural beliefs (Steingraber, 2000; Epstein 2003; Knope-
Newman, 2004:845-874; ACS 2006; NCI, 2006).  Of these choices, smoking has been 
linked to lung cancer and alcohol consumption has been shown to increase the risk of 
certain cancers, such as liver cancer (Anatomy of the Breast, 2003; Epstein & Steinman, 
1997:2-10, ACS 2006; NCI, 2006).  
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There is a great deal of research that points to a diet high in fat as one of the 
causes of breast cancer.  Studies have been conducted to show that diets high in animal 
fats and low in fiber can lead to higher rates of breast cancer (Wallis, 1991).  The high fat 
diet seems to coincide with the lack of exercise and research has shown that exercise can 
actually reduce the risk of acquiring breast cancer (Anatomy of the Breast, 2003, Epstein 
& Steinman, 1997).  Though the evidence is weakly linked to actually impacting breast 
cancer rates, generally speaking, individuals who engage in regular exercise tend to have 
a better diet and are less likely to have bad habits such as smoking (Steingraber, 2000; 
Moss, 2002).  Another factor that may link diet and breast cancer involves food 
production.  The majority of food produced tends to have additives, pesticide residues, 
and endocrine disruptors which have been linked to the development of cancer (Brody, 
2005).  Also, pollution of the water supply and air quality can have an impact 
(Steingraber, 2000).   
Female reproductive factors and behaviors are also considered as major lifestyle 
choices that influence the risk of developing breast cancer (NCI, 2006; ACS, 2006; 
Anatomy of the Breast, 2003).  The two main reproductive factors and three behaviors 
that attribute to increased breast cancer risk are: age of first menstrual period, age at the 
onset of menopause, using the birth control pill, age of first full-term pregnancy, and 
breastfeeding (Bernstein, 2002).   
The literature suggests that a woman who has her period before the age of 12 or a 
woman who begins menopause at or after age 55 is more likely to have breast cancer 
(Epstein & Steinman, 1997).  This is because of increased exposure to estrogen.  
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Estrogen is the hormone released when menstruation begins.  Menstruation at an early 
age increases the length of exposure to estrogen.  Later onset of menopause also increases 
the length of time a woman is exposed to estrogen, since estrogen is associated with both 
menstruation and menopause (Epstein & Steinman, 1997).  Though this research does not 
provide conclusive data about the role of estrogen as a carcinogen or how to control 
estrogen levels, it is considered to be a risk factor for breast cancer (Bernstein, 2002; 
Susan G. Komen Foundation, 2006).  The other interesting issue with these two lifestyle 
risks is that women do not have control over the onset of their periods or onset of 
menopause, and estrogen is a naturally occurring hormone within the female body; how it 
becomes a carcinogen requires additional research (Steingraber, 2000).  Other exposures 
to estrogen may come from using the birth control pills which contain varying 
concentrations of estrogen (Epstein & Steinman, 1997).  The pill generally contains 
estrogen and progesterone, and, as mentioned earlier, estrogen is a known carcinogen for 
breast cancer (Epstein, 2003).    
The age of first full-term pregnancy is also a lifestyle choice that is implicated as 
a risk factor for breast cancer.  Research suggests that having a child prior to age 30 
seems to have a “protective effect” against breast cancer (NCI, 2006).  Though the 
mechanism of how this protective effect works is still unknown, it is considered one of 
the lifestyle choices that can protect a woman against breast cancer (Sturgeon, 1995).   
 Breast feeding is also a lifestyle choice that is considered as a risk factor for 
breast cancer (Epstein & Steinman, 1997).  There is research underway to determine 
whether or not breastfeeding has a protective effect against breast cancer.  The current 
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thinking is that breast feeding for more than a year will have a protective effect and less 
than a year will not (Newcomb, 1997; Bernier M, 2000:374-386).  The other issue that 
complicates breast feeding and the risk for breast cancer involves the chemical body 
burden of the mother and how much of the chemicals she will pass to the child through 
the breast milk (Epstein & Steinman, 1997).  
Though cultural beliefs and social status are not usually considered lifestyle 
choices, both of them can impact an individual’s ability to make lifestyle choices.  There 
are many health behavior models which emphasize the role of cultural beliefs on the 
perception of health and the cues to action that will lead to behavior change and even 
seeking medical care (Epstein, 2003). One of which is the Health Belief Model (HBM).  
The key concepts of the HBM are: perceived susceptibility, perceived severity, perceived 
benefits, perceived barriers, cues to action, and self-efficacy (Glanz, 1997).  The HBM 
emphasizes the role of cultural beliefs on perceived susceptibility of breast cancer as a 
potential reason for minority women not seeking medical care for breast cancer. One of 
the current prevention strategies for breast cancer is “early detection” through screening.  
Screening or early detection can be accomplished by a self exam of the breast, medical 
exam, or a mammogram (Kopans DB. 2000, MMWR, 1997 & Iezzoni LI, 2001). Based 
on the HBM, a woman may be less likely to engage in “early detection” activities, if her 
cultural beliefs deemphasize such activities.   
 The role of cultural beliefs and access to care may explain why breast cancer 
statistics show that though Caucasian woman have higher incidence rates of breast 
cancer, African-American and other minority women are more likely to die from breast 
cancer (NCI; ACS; and Epstein, 2003).  Given the fact that cultural beliefs significantly 
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influence health behavior and cues to attaining medical care and that screening is a key to 
preventing and controlling breast cancer, the reasons for higher rates of Caucasian 
women getting breast cancer and more minority women dying from breast cancer may be 
linked to cultural beliefs (ACS, 2000 & CDC, 2004). Caucasian women are more likely 
to receive routine medical care, unlike their minority counterparts who may be less likely 
to seek medical care, due to access to health care issues or beliefs associated with their 
culture (Epstein, 2003).  These issues may explain why minority women are more likely 
to die from breast cancer because when the cancer is finally detected, it is often too late 
for medical intervention (Breast Cancer Action, 2006).   Listed below are some graphs 
that show how the incidence rate for breast cancer has risen and the variation in the 
incidence and mortality rates for all women by race (NCI, 2005). 
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Figure P-2: Incidence and Mortality Rates: for Breast Cancer National Cancer Institute “A Snapshot of 
Breast Cancer”.  
 
Coupled with cultural beliefs is social status.  Social status can be defined as an 
individual’s race, gender, level of education, or Socioeconomic level; therefore social 
status tends to impact an individual’s cues to action for medical care (Glanz,1997; 
Epstein 2003; Moss 2002).  An individual’s social status plays a big role on the amount 
of exposure that she or he has to a hazardous environment (Bryant, 1995; Hofrichter, 
2000). Low Socioeconomic Status, being a minority and having a low educational level 
can impact an individual’s ability to obtain medical care and can play a strong role in 
lifestyle choices.  For example, minority women are less likely to get a mammogram 
because they are less likely to be able to afford it (Epstein, 2003).  Also, these women 
may be more likely to live in polluted environments which contain the carcinogens and 
endocrine disruptors that cause breast cancer.   
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Environmental Justice (EJ) literature has shown that an individual’s proximity to 
environmental carcinogens is based on social status (Bryant, 1995; Hofricter, 2000). The 
Environmental Protection Agency (EPA) defines EJ as: “the fair treatment for people of 
all races, cultures, and incomes, regarding the development of environmental laws, 
regulations, and policies” (EPA, 2005).  Another definition is “the pursuit of equal justice 
and equal protection under the law for all environmental statutes and regulations without 
discrimination based on race, ethnicity, and/or socioeconomic status.  The EJ literature 
has shown evidence that minorities and people with low Socioeconomic Status are more 
likely to live near environmental hazards, some of which may contain the environmental 
carcinogens that can be linked to causing breast cancer (Bryant, 1995; Hofricter, 2000).  
The Health Behavior Model coupled with the environmental justice literature 
suggests that the role of an individual’s lifestyle choices may be less responsible for 
causing breast cancer; instead it may be the social processes which produce the 
environmental carcinogens.  Based on the information about lifestyle choices, very few, 
if any, are really at the discretion of the individual.  Most of the lifestyle choices are 
connected with the individual’s surrounding environment.   
The Environment 
The role of exposure to environmental pollutants and carcinogens leading to 
negative health impacts have been studied since the 1800s and conclusive evidence of 
adverse health effects from carcinogenic chemicals have been reported since 1940 
(Tomatis, 2004).   The evidence about the dangers of pesticides to the environment and 
human health reached the public with Rachel Carson’s book Silent Spring.  Later Sandra 
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Steingraber’s The Social Production of Cancer: A Walk up Stream provided additional 
evidence to support the link between environmental carcinogens and cancer (Stiengraber, 
2000). The Long Island and Cape Cod Studies, two research projects conducted in the 
late 90’s, further strengthened the evidence for the connection between environmental 
pollutants and breast cancer (Brody, 2005 & Glazer, 2005). Chemicals produced by 
industrialization and a technocratic way of life are not the only environmental 
carcinogens.  Radiation and everyday items, such as household cleaners and cosmetics, 
are all contributors of breast cancer (Brody, 2005).  Some of these items contain 
chemicals that are endocrine disruptors (Solomen, 2002).   
Endocrine disruptors have been studied since the 1930s in laboratory animals.  
These animal experiments revealed that certain industrial chemicals impacted not only 
the animal exposed, but also the offspring (Solomon, 2002).  In the 50s a similar impact 
was noted from pesticides and later written about by Rachel Carson in the book Silent 
Spring.  Carson alluded to the endocrine disruptor process and the impact on the 
environment and human health. This book sparked immense negative feedback and 
attacks on Carson from the pesticide industry and the government (Lear, 1997). 
Endocrine disruptors are the hazardous chemicals that work by binding to or 
blocking hormone receptors (Solomen, 2002).  This binding and/or blocking of hormone 
receptors leads to dysfunctional transcriptions of genes and the production of genetic 
mutations (Cooper, 1997: 159-166).  These mutations are often passed down to the 
offspring and can eventually lead to the production of abnormal cells and cancer 
(Solomon, 2002).  The endocrine disruptors that impact breast cancer are in a special 
category called the Mammary Endocrine Disruptors (Brody, 2005).  Mammary endocrine 
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disruptors seem to play a key role in the development of breast cancer cells and genetic 
mutations.  The majority of these endocrine disruptors can be found in household 
products used by women, including: beauty products, home furnishings, detergents, and 
plastics (Brody, 2005).   
Environmental carcinogens and the role of the environment have surfaced as 
contributing factors for the other two causes of breast cancer: genetics and lifestyle 
choices.  In the case of genetics, environmental carcinogens have been shown to be a 
potential cause for DNA mutations.  In the case of lifestyle choices, environmental 
carcinogens can impact diet and reproductive health.  All of these issues combined, lead 
to questions about the actual role of the environment and environmental carcinogens as a 
cause of breast cancer, and how much research is being conducted to identify and 
mitigate these environmental carcinogens.  
Figures P-3 shows incidence rates for breast cancer by states and Figure P-4 
shows the states or areas that have active sites that are on the Super Fund and the 
National Priorities Lists (NPL) (EPA, 2006).  To date there has been little to no research 
that correlates the rates of breast cancer incidence with where an individual lives and the 
proximity of this location to sites containing environmental carcinogens.  If these maps 
were superimposed, the states which have many Superfund and NPL Sites are also the 
same states that have the higher rates of breast cancer incidence.  The east coast seems to 
have higher rates of breast cancer and environmentally hazardous sites (Evans, 2006).  
Though simply superimposing the maps would not be evidence enough,  research funding 
policies have yet to conduct research on the correlation between breast cancer rates and 
proximity to these environmentally hazardous sites (NCI and ACS, 2005).  
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Figure P-3: Incidence and Mortality Rates by State: National Cancer Institute “A Snapshot of Breast 
Cancer”.  
 
 
 
 
 
 
 
 
 
 
Figure P-4 NPL Sites by State: for the United States based on current EPA data.  
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The role of the environment as a causative agent for breast cancer is further 
supported by reports such as State of the Evidence: What is the Connection Between the 
Environment and Breast Cancer.  This type of report has been published annually for a 
number of years and it demonstrates that there is substantial scientific evidence which 
links exposure to radiation and synthetic chemicals to an increased risk of breast cancer. 
The report provides findings from more than 350 experimental, epidemiologic and 
ecological studies and the need to act on the evidence and reduce human exposure to 
environmental carcinogens such as radiation and synthetic chemicals.  A multitude of 
environmental chemicals which have been linked to breast cancer occurrence are 
documented in this report, the most common of which are listed below (Evans, 2006):  
 Bisphenol-A (BPA): a chemical used to make polycarbonate plastic; 
 Diethylstillbestrol (DES): a drug that has now been banned for decades but was 
prescribed to women to prevent miscarriages; 
 Polyvinyl Chloride (PVC): found in plastics used for food packaging, medical 
equipment, appliances, cars, toys, and even credit cards; 
 Dieldrin: a pesticide that has been banned, but is still persistent in the 
environment from where it was used; 
 Aromatic Amines: which are a class of chemicals found in the air, water, plastics, 
diesel exhaust, tobacco smoke, and grilled meats.  O-toluidine is an aromatic 
amine that has been linked to mammary tumors in rodents;  
 1,3-Butadiene: a carcinogen that is found in the air and has been on the 
Environmental Protection Agency’s (EPA) list of know human carcinogen’s list, 
yet it is still emitted into the air; 
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 Polycyclic Aromatic Hydrocarbons (PAHs): found in fumes, cigarette smoke, and 
are produced during grilling and other processes; 
 DDT and PCB’s: though both have been banned from use in the United States for 
decades, they are still present in the environment and can be found in fatty tissue 
and breast milk; 
 Dioxins: chemicals are highly prevalent in the environment and can be found in 
humans; (Evans, 2006). 
The list above represents just a few of the chemicals that are known carcinogens 
which may cause breast cancer (Evans, 2006).  The impact of environmental carcinogens 
on health is also emphasized in books, such as Joseph LaDou’s Occupational and 
Environmental Medicine, a textbook used in medical and environmental science 
curriculums (LaDou, 1997).  However, the information about role of the environment on 
health outlined in this and other textbooks is not usually public knowledge (Steingraber, 
2000).   
Devra Davis, in her book When Smoke Ran Like Water, provides a historical 
narrative about the role of the environment on the occurrence of breast cancer in a 
chapter entitled: “The New Sisterhood of Breast Cancer”.  This chapter tells the story of 
Bella Abzug and how she convened a  public hearing in New York City to find out why 
research funding policies remain  focused on treatment, when no new treatments have 
been developed in over two decades (Davis, 2002: 181).  Davis touches on the role of 
patriarchy as she shares how there has been a change in the discourse of breast cancer and 
how the disease went from being whispered about to breast cancer becoming a national 
agenda item (Davis, 2002: 181).   
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Though it is true that breast cancer has become a national agenda item, research 
funding policies still tend to focus on genetics and lifestyle choices through new medical 
treatments and screening methods (Davis, 2002:159-192).  Over 85,000 synthetic 
chemicals are in use today to make everything from lipstick to furniture to the plastics in 
water bottles and pesticides (Evans, 2006).  Still less than 5% of available funding is 
dedicated towards research activities that evaluate the role of these carcinogens on breast 
cancer (NCI, 2006). 
Ionizing radiation can also be attributed as a cause for breast cancer and genome 
instability (Evans, 2006; 20-45).  It is a form of radiation that contains enough energy to 
cause cancer and this form of radiation is utilized in mammography, X-rays, and other 
areas of the environment (Evans, 2006).  Although it has been suggested, that there are 
“safe doses” of radiation, there is no conclusive research evidence to prove that radiation 
at any level is safe (Evans, 2006).  There seems a great deal of literature that points to the 
environment as a cause for breast cancer and the need for funding research activities 
which include the role of environmental carcinogens; however, most of this literature 
does not ask why current research funding policies do not emphasize such research 
activities.   
 
Current Research Funding Priorities  
 As mentioned in the History and Etiology section of this chapter, the research 
funding policies for breast cancer are established by the National Cancer Institute (NCI) 
and the American Cancer Society (ACS).  These agencies work together to raise 
awareness about breast cancer and provide reports and feedback to members of Congress 
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about what is currently being researched and what should be researched.  The NCI and 
ACS make suggestions for what items should receive appropriations from Congress.  
Congress conducts appropriation hearings where testimony is given about what should be 
funded and why.  The funds are appropriated to NCI and this agency issues Requests for 
Proposals (RFPs) for research funding.  Based on the RFPs, NCI then releases the funds 
for research activities.  Though ACS supports the research priorities set by NCI, ACS 
determines it own research priorities and decides how the funds that are raised through 
donations will be spent (NCI and ACS, 2006).  
Research has identified three main causes for breast cancer: genetics, lifestyle 
choices and environmental carcinogens.  The literature has shown that only 30% of breast 
cancer cases can be directly linked to genetics and lifestyle choices, while the remaining 
70% may be linked to the environment. Despite this fact, current research funding 
policies continue to focus the bulk of available funding on first two causes (Epstein & 
Steinmen, 1997:2-10; Epstein, 2003; Evans, 2006).  There seems to be a disparity 
between the number of breast cancer cases that can be linked to a particular cause and the 
ratio of funds that are spent on research activities to reduce the impact of that cause.  This 
disparity raises questions about how and why certain causes are funded and others are 
not. 
 
Two Main Discourses 
 A review of the literature has identified two main discourses to answer these 
questions about the funding disparities: the conventional discourse and the alternative 
discourse.  The conventional discourse explains existing research funding policies as set 
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by the NCI and ACS.  The alternative discourse utilizes the “Cancer Establishment” and 
the “Cancer Industry” to explain the research funding policies.  
 
Conventional Discourse: ACS & NCI  
The Conventional Discourse consists of the NCI and ACS and their current views 
about research funding policies for breast cancer.  The NCI was formed by the passing of 
the National Cancer Act in 1971 and this agency has been conducting research to fight 
cancer since that time.  The mission of the NCI is (NCI, 2007): 
“The National Cancer Institute (NCI) is a component of the National 
Institutes of Health (NIH), one of eight agencies that compose the Public Health 
Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, 
established under the National Cancer Institute Act of 1937, is the Federal 
Government's principal agency for cancer research and training. The National 
Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created 
the National Cancer Program. Over the years, legislative amendments have 
maintained the NCI authorities and responsibilities and added new information 
dissemination mandates as well as a requirement to assess the incorporation of state-
of-the-art cancer treatments into clinical practice.  
The National Cancer Institute coordinates the National Cancer Program, which 
conducts and supports research, training, health information dissemination, and 
other programs with respect to the cause, diagnosis, prevention, and treatment of 
cancer, rehabilitation from cancer, and the continuing care of cancer patients and the 
families of cancer patients. Specifically, the Institute:  
• Supports and coordinates research projects conducted by universities, hospitals, 
research foundations, and businesses throughout this country and abroad through 
research grants and cooperative agreements.  
• Conducts research in its own laboratories and clinics.  
• Supports education and training in fundamental sciences and clinical disciplines 
for participation in basic and clinical research programs and treatment programs 
relating to cancer through career awards, training grants, and fellowships.  
• Supports research projects in cancer control.  
• Supports a national network of cancer centers. 
•  Collaborates with voluntary organizations and other national and foreign   
institutions engaged in cancer research and training activities.  
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• Encourages and coordinates cancer research by industrial concerns where such 
concerns evidence a particular capability for programmatic research.  
• Collects and disseminates information on cancer.  
• Supports construction of laboratories, clinics, and related facilities necessary for 
cancer research through the award of construction grants.”  
 
Funding for breast cancer research is a major priority for NCI.  Figures P-5 shows 
NCI’s current funding priorities for breast cancer research.   The bar graph in this figure 
shows that NCI’s funding for breast cancer research has increased since the year 2000.  
The pie chart shows how this funding is distributed and the overall funding priorities: 
early detection through screening, treatment, causes, biology, and survivorship programs 
receive the bulk of the funding.  These research priorities connect with two of the three 
causes that have been discussed: genetics and lifestyle choices.   The third cause linked to  
breast cancer, environmental carcinogens, is not shown on this pie chart; though the NCI 
does spend about 5 % of the annual research budget on the role of the environment as a 
cause for breast cancer.   
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Figure P-5: Research Funding Investment: “A Snapshot of Breast Cancer”. 
 
 
The American Cancer Society (ACS) was founded in 1913 by physicians and 
business leaders in New York City.  Since its formation, this organization has been 
working to raise awareness about cancer, conducting research for treatment and cure, and 
providing support for cancer survivors and victims.   The mission of the ACS is (2007): 
“The American Cancer Society is the nationwide community-based 
voluntary health organization dedicated to eliminating cancer as a major health 
problem by preventing cancer, saving lives, and diminishing suffering from cancer, 
through research, education, advocacy, and service”. 
 
The ACS raises a great deal of funds to help fight cancer.  They use these funds to 
support many activities related to cancer including research.  Breast cancer is one of the 
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cancers which receives research funding from the ACS. The funding priorities for these 
research activities are bulleted below (ACS, 2006): 
 “The money raised through Making Strides Against Breast Cancer helps 
the American Cancer Society fight breast cancer by … 
 Funding cutting-edge research leading to the discovery of lifesaving 
treatments like Tamoxifen and Herceptin. In fact, the Society has invested 
more in breast cancer research grants over time than any other voluntary 
public health organization – $322.7 million since 1972 and, it was the 
American Cancer Society that established mammography as the gold 
standard for the early detection of breast cancer.  
 Offering the nation’s only 24-hour cancer hotline (1-800-ACS-2345), 
where people fighting cancer can turn anytime, day or night to talk to a 
Cancer Information Specialist (Information is available in many 
languages.)  
 Providing free programs and services that improve the quality of life for 
cancer patients and their families in more than 3,400 communities across 
the country  
 Providing free email mammogram reminders, and a program called 
Reach to Recovery® that matches newly diagnosed breast cancer patients 
with survivors who can guide them through their journey with the disease  
 Offering a state-of-the-art Web site (www.cancer.org) where patients can 
learn how to reduce their cancer risk, find hospitals, learn about 
treatment options and clinical trials, and more  
 Advocating for public policies that provide all women access to 
mammograms and breast cancer treatment, regardless of income 
 Since 1993, 3.5 million walkers across the country have raised more than 
$230 million through Making Strides events to help fight breast cancer. 
Thanks to people like you, the American Cancer Society provides help and 
hope to thousands of breast cancer patients.” 
The ACS also focuses the bulk of the funds that are raised for breast cancer on 
research activities which focus on genetics and lifestyle choices.  The role of the 
environment as a cause is not a research priority for the ACS, based on the information 
provided above.   
The National Cancer Institute and American Cancer Society support funding for  
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research activities which target genetics and lifestyle choices.  The NCI and ACS provide 
the following explanations for the increased incidence of breast cancer and their research 
funding policy focus: 
 women are living longer and there are better screening methods to detect 
breast cancer earlier when possible;  
 it is difficult to study the effects of the environment and conclusively 
pinpoint how environmental carcinogens cause breast cancer;  
 medical treatment saves lives once the disease has been contracted;  
 raising awareness about the impact the lifestyles choices can lead to 
adequate prevention activities (NCI & ACS, 2006).   
 data about the role of environmental carcinogens is not readily available 
and there is limited understanding of how these carcinogens and endocrine 
disruptors work (NCI & ACS, Davis, 2002).  
 
Alternative Discourse: Cancer Establishment & Cancer Industry 
The alternative discourse consists of the Cancer Establishment and the Cancer 
Industry.  Samuel Epstein, a professor and the Chair of Environmental Medicine at the 
University of Illinois, School of Public Health, who has published hundreds of journal 
articles as well as authoring and co-authoring 10 books; uses the term “Cancer 
Establishment” for the “the powerful lobby” which encompasses: NCI, ACS, and the 
twenty or more comprehensive cancer centers funded by NCI and ACS (Epstein, all three 
references).  He explains that the “Establishment” is influencing research funding policies 
and hence deciding what to include and what to exclude in the national research agenda 
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and activities for cancer, specifically breast cancer (Epstein S.S, 2003; Epstein S.S, 
1998,: Epstein S.S, 1997).   
In his book Breast Cancer Prevention Program, Epstein goes into detail about 
how for the past two decades the Cancer Establishment has received and spent well over 
$20 billion dollars on the war against cancer, and the rates for cancer, specifically breast 
cancer are still on the rise.  The Establishment continues to focus on research into 
genetics, screening, and treatment options, instead of the environmental carcinogens that 
can be specifically linked to the disease.  Epstein explains that the Cancer Establishment 
sets the policy agenda for cancer funding research activities, including the research 
agenda for breast cancer.  
Epstein and others who agree with the notion of the “Establishment” have 
published several books and reviewed well over 2,500 publications and documents which 
all seem to conclusively point to the fact that breast cancer can be prevented through the 
mitigation of environmental carcinogens and by limiting exposure to these carcinogens 
(Evans, 2006). 
Epstein goes further to explain that the Cancer Establishment has a vested interest 
in keeping the research funding policies focused on screening, treatment, and basic 
genetics, rather than prevention by limiting exposures to environmental carcinogens.  The 
Establishment consists of powerful appointed leaders who have conflicts of interest due 
to interlocking financial investments between those in power at NCI, ACS, and the 
pharmaceutical industry; also there has been a continual pattern of employment of 
pharmaceutical industry CEO’s as the Directors of NCI; profit from drug development 
and marketing; ACS’s connections to the mammography industry; and the media 
   
 
36
campaigns which create smoke screens and legitimize the funding decisions.  Epstein’s 
view on cancer research, specifically breast cancer research can be summed up by the 
following quote: “Whether against cancer or terrorism, war is best fought by preemptive 
strategies based on prevention rather than based reactively on damage control.  As 
importantly, the war against cancer must be waged by leadership accountable to the 
public interest and not to special agenda private interests.” (Epstein et al, 1997, 669-707).    
Based on his research, Epstein outlines the “dirty dozen”, the risk factors that 
women can avoid to prevent breast cancer.  The “dirty dozen” list includes: prescribed 
oral contraceptives; estrogen replacement therapy; premenopausal mammography; 
nonhormonal prescription drugs, such as anti-depressants; silicone breast implants; diets 
high in animal fat containing hormones; household chemicals; proximity to hazardous 
waste sites; occupational exposures to carcinogens; inactivity; dark hair dies; and 
prolonged alcohol and tobacco use (Epstein & Steinman, 1997:9).  Though he provides a 
plan for how women can prevent breast cancer by becoming aware of and limiting 
exposure to the risk factors, and he alludes to the Cancer Establishment having a vested 
interest in treatment and screening research; however, Epstein’s concept of the Cancer 
Establishment does not explain the mechanisms of how and why the research funding 
policies exclude the environment.  The concept of the Cancer Establishment points to 
powerful leaders setting the agenda for research funding policies; it does not explain the 
role of power in agenda setting and socializing American society to accept the existing 
breast cancer research funding policies as adequate.   
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The Cancer Industry 
The Cancer Industry is a concept which emerges from a book by Ralph Moss 
(Moss, 2002).   Moss is a well known medical writer who has been studying cancer 
policies since the 1970’s.  He defines the “Cancer Industry” as the underlying economic 
system or mechanism of profit making that excludes research into environmental 
carcinogens, prevention, and alternative medicine, because they are less profitable.  He 
declines the notion of the agencies utilizing power to maintain their agenda, rather he 
blames the economic and social systems in place that are driven by profit (Moss, 2002).  
He does agree that the “ruling class” in cancer research is comprised of pharmaceutical 
companies which have emphasized the dominant discourse of medical treatment instead 
of prevention; however, this ruling class is more influenced by the economic system of 
profit which suppresses the less profitable methods (Moss, 2002).   
The “Industry” consists of the government, medical centers, drug companies, 
equipment manufacturers, and the media (Moss, 2002).  Together they act to suppress the 
less profitable treatments and call them unorthodox methods that do not have proven 
results of success (Moss, 2002).  The Industry wants to continue to engage in drug 
therapies and screening methods which may actually be sources of the carcinogens that 
contribute to breast cancer.  The Industry defines the medical treatment practices and 
research funding and policies.  Most research funding policies are fixated on secondary 
and tertiary prevention- through screening and medical treatment, when research should 
also focus on the elimination of environmental carcinogens leading to primary prevention 
(Epstein, 2003).   
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This system or predominant Industry is driven by profit from screening and 
treatment techniques, such as mammography and chemotherapy.   In fact, he calls the 
NCI the political pharmacy where new drug therapies are formulated to fight breast 
cancer and the research on prevention, the environment, and alternative medicine are 
discouraged (Moss, 2002).  Though there have been programs developed to investigate 
alternative medicine, these programs receive little to no funding for research activities. 
The mechanism of discouragement takes form through restricting research on certain 
topics by decreasing or eliminating funding (Gennaro, 2005:356-359).  Though science 
can contribute to prevention, environmental, and alternative medicine research; 
unregulated scientific research can have the potential to topple this Industry (Moss, 
2002).  Therefore, the Cancer Industry, for sake of self preservation, has mechanisms in 
place to control scientific research that may impact the profit margin (Moss, 2002).         
The Cancer Establishment and the Cancer Industry combine to form the 
alternative discourse for explaining why research funding policies for breast cancer may 
be decided. The next section will utilize Sociology and Policy Theories to expand this 
discourse and provide insight into why power and market systems may influence breast 
cancer policies and how these influences impact the policy process.  
 
Theoretical Framework 
Social Theory 
Sociology can provide background for the influence that power and economics 
can have through scientization of politics on the policy process.   For the purposes of this 
study, power will be defined by two social theorists and an attempt will be made to 
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explain the role of power in breast cancer research funding policies.  The first is Steven 
Lukes.  Lukes is known for defining the “Three Faces of Power” or the three levels of 
power a government has to create social order in a given society and to legitimize views 
and rules of those in power.  These three levels are:   
1) The public process of policy making where the prevailing public and opposing 
parties are involved in decision making or defining the winner;   
2) Agenda setting or framing which is more subtle, yet very powerful because it 
is not as obvious; 
3) The power to socialize people so that they reflect the view of the person in 
power (Lukes, 1974). 
These three levels of power can drive the policy process.  An example of the first 
would be the questions that are placed on a ballot for the general public to vote.  The 
public votes yes or no and decides the outcome.  This level of power tends to be more 
obvious and not as heavily utilized to determine policy.   The second level of power, 
agenda setting, is utilized heavily in policy process.  An example of this level would be 
process of deciding which questions will appear on the ballot for voting.   The third level 
of power involves actually shaping the view of individuals so that they reflect the 
ideology of those in power.  Using the example of the questions on the ballot, this level 
of power would actually shape the view of the voters so that they vote in favor of the 
ideology in power (Lukes, 1974). 
Of these three levels of power, the latter two: the power to set agendas and 
socialize people are used to influence the research funding policies for breast cancer.  
Though the policy makers and the general public may believe that science is driving the 
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research activities towards funding for two of the three causes, genetics and lifestyle 
choices; the truth is that leaders of the NCI and ACS may be determining the research 
agendas for breast cancer and other diseases.   
NCI and ACS set the agenda for breast cancer research activities by: influencing 
appropriations for research and prescribing research activities that will be funded.   
Influencing appropriations occurs during Congressional hearings and the prescribing 
research of activities occurs once the agency receives the funds.  
The type of agenda setting that can occur during the hearing process can be 
explained by the “scientization of politics”.  The Scientization of Politics is a theory 
developed by Jurgen Habermas and later utilized by Urlik Beck in the book Risk Society. 
This theory explains how science has become encapsulated by governmental 
bureaucracies and involves a research process which is defined by technical applications; 
rather than by research for the sake of solving problems.  Scientific knowledge and 
research results are no longer communicated to the public and instead the information is 
controlled by experts.  Decisions that should be made based on politics and morals, are 
transferred into scientific arenas which complicate the fact and exclude the public. The 
public has no real dialog about science, creating a non-democratic state which seems to 
exclude the public completely. Science has become a contracted set of research activities 
which agencies and politicians can use science and scientific experts to provide data for 
the cause they want to be validated or legitimized (Habermas, 1970: 62-80; Beck, 1992).  
Science can no longer explain away the risks to the public, since there are scientific 
experts employed by the government and industry with conflicting interpretations about 
the research results leading to inconclusive decisions by the government and no answers 
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about the risk associated with this technocratic society for the public.  Science is no 
longer the pure search for solutions, rather it has become a competition between experts 
on both sides of the issue and in the end the results are influenced by the industries 
funding the scientific research, instead of the actual research data (Fischer, 2000: 87-108)   
Breast cancer research involves conflicting views from different scientific experts 
and theses conflicts are emphasized during the policy process for research funding.  
Politicians have influence over the type of funding and who should receive that funding 
for breast cancer research activities and the scientist that perform these activities.  The 
scientists reinforce the politicians’ decisions with scientific data leading to the 
scientization of politics (Habermas, 1970: 62-80).  Since the environmental causes of 
breast cancer could lead to the toppling of the industries which produce the pollution; 
scientific experts are utilized to provide inconclusive data which cannot establish the risk 
from the sources of pollution and the true risk is not communicated to the public. 
This scientization of politics reinforces how the second level of power can 
influence breast cancer research funding for certain causes instead of others during the 
policy process in the United States.  Those in power are not only defining the dominant 
discourse for research funding; they are also developing methods of legitimizing their 
funding decisions by utilizing empirical testing and data to support their decisions 
(Camhis, 1979).  Scientific experts provide politicians with the research agenda and data 
to support current research funding focused on two of the three causes.  These agendas 
are presented at Congressional hearings and supported by the testimony presented by 
those who appear at the hearings to drive the research funding policies.  Policy makers 
are provided with status reports on current research activities, along with the results and 
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statistics which promote or demote certain research activities (NCI & ACS reports).  
Hence, the agenda setting becomes a powerful tool to maintain the existing research 
funding activities. 
The Sociology of Science is a sociological concept that can add to this discussion 
of the scientization of politics.  This concept explains that science is more than the search 
for the truth or answers to unexplainable phenomenon as it was in the time of Newton or 
Einstein; it has become a cultural tradition and as such has been institutionalized (Ben-
David and Sullivan, 1975:203-222).  Just as science can impact the societal activities 
such as the creation or reduction of pollution through different technology; societal inputs 
can impact the nature of scientific activities.  For example, one of the main activities of 
science is research and these research activities are now directly impacted by grant 
funding.  No longer does a scientist conduct research without some form of grant funding 
from an institution.  The institution provides research funding if the proposed research 
activities match the issues the institution wants to have researched.  The science of 
sociology examines how science is controlled and maintained by the virtue of the 
research activities and the fact that science no longer determines the unexplained 
phenomenon to be researched; the government and industry set the research agendas 
(Ben-David and Sullivan, 1975:203-222). 
Research activities can lead to scientific discoveries and impact changes in 
sciences and future research activities.  So the organizations which control the research 
funding not only impact current research activities; but also future research and science 
as a whole.  Science is no longer the quest for individual knowledge for the betterment of 
society; it now consists of research activities that are controlled heavily by funding and 
   
 
43
societal norms which dictate these activities (Gentili, 2000: 12-18).  Governmental 
institutions, academic universities, and industry define the norms or acceptable research 
activities; research activities that may be considered as deviant or challenge the accepted 
norms are often excluded from receiving research funding (Agnew, 1998: 6-7).  Science 
has become an institution which conducts research activities that will provide economic 
benefits to the organization that is granting the funding for the research activities.  The 
science of sociology explains how science has moved away from the individual quest for 
knowledge to an institution which is controlled by the privatization of research funding 
and those agencies which set the research agendas.  
This leads to the prescribing of funding for research activities which occurs 
during the agenda setting of Request for Proposals (RFPs) for grant funding.  RFPs are 
issued and researchers and agencies, such as universities, compete for funding.  The 
agenda setting is accomplished in the RFPs by prescribing the types of research activities 
that will be funded (Epstein, 2003; Moss, 2002).  Agencies which submit proposals that 
do not align with the prescribed agenda for research activities are not funded (Epstein, 
2003).   
The third level of power is also utilized for setting the policies for funding breast 
cancer research.  This level of power involves shaping the view of individuals so that 
they reflect the ideology of those in power. In the case of research funding policies for 
breast cancer, the pink ribbon has been engraved into American society convincing the 
people that an annual fundraising campaign is enough and questioning research funding 
policies or where the funds raised through donations are going is unnecessary (Kolker, 
2004:820-844).  This ribbon can be identified as a breast cancer symbol by even a small 
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child.  This disease has received a great deal of press and though the press has helped 
women to not have to suffer in shame; it has also created a false sense of hope, 
socializing women to believe that the annual “Race for the Cure” and wearing a pink 
ribbon is enough (Epstein, 2003, Kolker, 2004:820-844).    
The other aspect of using power is also emphasized by the alternative discourse 
and how the NCI and ACS exercise their power in the area of breast cancer research with 
intention.  The notion of using power with intention coincides with Mike Foucault’s 
definition of power. Foucault explains that knowledge and power combine to define the 
dominant discourse which sets up what is normal and abnormal (Foulcault, 1990, 1995). 
This dominant discourse of normal and abnormal is then adopted by those in power and 
their view is reflected in the research funding policies.   
Foucault emphasizes the role of how shared ideas, or paradigms, change or shift 
based on old theories being challenged and replaced with new theories to form dominant 
discourses.  He explains that dominant discourses are formed because of power and by 
those in power.  Power is what drives the shifts in paradigms.  Those in power, use the 
power to impose their own paradigms on the community (Skinner, 1985:Chapters 6 & 7).  
Power is used to define the dominant discourse for research funding policies for breast 
cancer.  
Power is also used to influence the policy process and increase profit for the 
Cancer Industry.  How profit and the market system develop the ideologies which 
dominate the breast cancer funding policies, can be explained by Karl Marx’s theory 
about the capitalistic mode of production and Allen Schainber’s treadmill of production.  
In the capitalistic mode of production, everything, including all of the inputs and outputs, 
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become commodities and are commodified (Sweezy, 2004: 1-10).  At the top of this 
market system tend to be a small group of individuals pursuing interests, keeping each 
other in check by competition.  These inviduals are the “ruling class”, those who control 
the production or policy agenda and that set the ideologies in motion for the market 
system to run.  The purpose of this market system is to maximize profit, not provide 
services focused around people and their health or well being (Sweezy, 2004:1-10).  This 
theory of the mode of production emphasizes how the ideals of the Establishment and 
Industry become institutionalized in the decision making process to determine research 
funding outcomes for breast cancer (Sweezy, 2004:1-10).   Profit from medical 
treatments and screening methods drive the policies for funding and create a Cancer 
Industry. 
The notion of the Cancer Industry can also be captured by Allan Schainber’s  
“treadmill of production” (Foster, 2005:7-18).  The treadmill of production is a 
framework of analysis for environmental sociology and can be applied to the Cancer 
Industry.  In his article “The Treadmill of Accumulation”, Foster explains the six 
elements behind the logic of this concept: increasing accumulation of wealth by a small 
group of people in society; workers moving away from self-employment to wage jobs; 
competitive struggles between businesses leading to new technologies and expansion of 
production; an insatiable hunger for more; government increasingly promoting a national 
economy; and the dominant means of communication and education serve to reinforce 
the priorities and values of the treadmill of production (Foster, 2005).   
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The treadmill produces goods and is driven by consumption, regardless of the 
consequences.  Driven by the capitalistic constant need for more, production and 
consumption are increased, raw and natural resources are depleted at exponential levels 
and pollution is created (Sweezy 2004:1-10; Foster, 2005).  All resources are viewed as 
commodities, including medical treatments.  As production and consumption are 
increased, so are profits which drive companies to increase competition and advertising 
which influences the consumer choices and reinforces the cycles of production and 
consumption (Foster, 2005).  The Cancer Industry is an example of this treadmill of 
production.  The Industry is in this cycle driven by profit to produce treatment and 
screening options which produce more profit, thus making cancer a profitable industry 
(Moss, 2002).   
Another facet of what may be influencing research funding policies has to do with 
the role of patriarchy in the selection of those who decide on the research funding 
policies.  There may be a lack of a female presence on the voting boards of industry or 
government agencies which determine the research funding policies.  Due to the fact that 
breast cancer is a woman’s issue, patriarchy may play a role in determining the decision 
makers for research funding policies since women may not be present during the 
conversation that determines the policies for research funding.  Marxist Feminist theory 
can explain how women may be excluded.   
As Marxism speaks to the exploitation of the worker class by capitalism; 
feminism speaks to the exploitation of the female gender by patriarchy (MacKinnon, 
1982; Shelton and Agger, 1993; Hartsock, 1998).  Both of these theories point to notions 
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of oppression and just as the worker class may be excluded from participation in the 
policy process by capitalism; females may be excluded from participation in the breast 
cancer research funding policy process by patriarchy.  The theories presented earlier in 
this chapter have provided some of the potential reasons why the environmental causes of 
breast cancer have been excluded from research funding such as power and economics, 
Marxist Feminism may also provide evidence for the role of patriarchy in the policy 
process.  Therefore it is important to acknowledge the gender of those involved in the 
conversation that occurs about the breast cancer research activities and the research 
funding policies. 
 
 Policy Theories 
The social theories of power, scientization of politics, market system, and 
treadmill of production provide the background for why the research funding policies are 
made.  These theories can be associated with policy theories, to help better explain how 
these issues impact the policies that are made in the United States.  William Domhoff, 
explains several policy theories in his paper “Who Rules America?: Alternative 
Theoretical Views”.  These theories are: Pluralism, State Autonomy, Elite Theory, and 
Marxism.  These theories are defined below (Domhoff, 2005): 
 
 Pluralism: which is the theory that is based on the idea that different 
groups have power depending on the issue and that there is a free-market 
system; 
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 State Autonomy: explains that the government is an independent force that 
uses military control to maintain power; 
 Elite Theory: states that the leaders of large organizations or bureaucratic  
institutions dominate societies; 
 Marxism: emphasizes that property owners rule the policy process. 
  
Though there are other policy theories that can be used to explain the policy process, such 
as: Group Theory, Rationalism, and Systems Theory; for the purposes of this research 
only the Marxism and Elite Theory will be further expanded, since they best relate to the 
alternative discourse.  Since the Social Theory section of this chapter has discussed 
Marxism by explaining the market system and capitalistic mode of production; only an 
explanation of Elite Theory will be provided.  
 As defined above, Elite Theory attempts to explain how power relationships and 
economic stature impact the policy process.  This theory emphasizes how the small 
minority of individuals who hold economic power, control policy planning networks, 
which can lead to the policy agendas that are set and the policies that are implemented  
(Domhoff, 2005; Lavis, J, 2002). In the case of policies for breast cancer research 
activities, NCI , ACS, and other NGOs can be considered as the elites.   The model on the 
next page shows the policy process and how the two discourses may impact this process. 
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This model displays how the policy process for research funding occurs.  
Congress convenes hearings on policy issues associated with breast cancer, including 
policies for research funding.  Different agencies and actors are invited to testify at the 
hearings and based on the testimony, funding decisions are made and funds are allocated 
and awarded for research activities.  The conventional discourse emphasizes that the 
policy process is driven by science and the alternative discourse emphasizes that this 
policy process is driven by power and profit. 
Though Marxism and Elite Theory support the alternative discourse of Cancer 
Establishment and Cancer Industry; they do not capture the other parameters that are 
present in the policy process.  These two theories also do not explain fully how and why 
breast cancer policies are made and the role of the conventional and alternative 
discourses play in the determination of the actual research funding policies for breast 
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cancer.  The policy process is dynamic and it involves networks and feedback loops 
which facilitate change.  The Advocacy Coalition Framework combines the various 
components of the policy theories to explain how the policy process works (Blackburn, 
pp.54-58). 
The Advocacy Coalition Framework (ACF) can be used to determine policy 
outcomes in situations where there is conflict about what should be funded.  The ACF 
provides a mechanism for reviewing how competing advocacy coalitions, changes in 
external subsystems, and a stable system of parameters impact policies (Jenkins-Smith, 
1993).  The competing advocacy coalitions are the actors from public and private 
institutions at varying levels of government that share belief systems and work to 
manipulate the policies to match these beliefs.  The external subsystems are the economic 
and other systems that impact these coalitions in their quest to manipulate the policy 
process.  The stable system of parameters are the rules or the social structures that set the 
constraints for the policy process (Jenkins-Smith, 1993).   
The ACF explains that the policy process involves competition between the 
advocacy coalitions to establish and maintain core elements of public policy; as these 
dominant coalitions change over time so do the external subsystems and ultimately the 
policies (Jenkins-Smith, 1993).  The ACF has been utilized to study the policy process 
and better understand the coalitions or stakeholders and their influence on the policies 
that impact the environment and the role of the environment.  Weible, in his article 
entitled “An Advocacy Coalition Framework Approach to Stakeholder Analysis: 
Understanding the Political Context of California Marine Protected Area Policy”, utilizes 
the ACF to analyze the role of stakeholders in the political battle over protected areas for 
   
 
51
marine life in California.  He illustrates how the varying stakeholders work in the context 
of the ACF to promote their individual agendas (Weible, 2006). 
The ACF has also been used to describe coalitions and their impacts on 
automotive pollution control process.  The ACF was used in this automotive pollution 
study to determine how groups of actors coordinate their actions to compliment and 
achieve the overall policy objectives to coincide with their beliefs or ideas (Zanfonte, 
2004).  In this study the ACF is used to recognize the struggle over ideas and beliefs that 
occur during the policy process.  The ACF specifies that shared beliefs amongst actors 
leads to network relationships that align to form coalitions, unified discursive frames, and 
influence the policy process (Weible, 2005).    The ACF has been used to understand the 
policy process and to conduct policy analysis on other environmental issues and 
specifically with policy elites and how they engage to form coalitions to promote their 
shared belief systems and influence the policy process (Leach, 2005).  The ACF has been 
used in the analysis of air pollution and the formation of air quality policies where there 
are strong advocacy coalitions, and market systems in place to drive the policies in 
different directions. For these reasons, the ACF provides the framework needed to 
analyze the research funding policy process for breast cancer and determine how and why 
certain causes receive funding, while others do not (Jenkins-Smith, 1993).   
  In the case of research funding policies for breast cancer, there are actors and 
agencies who share certain core beliefs about research funding based on the conventional 
and alternative discourses.  The two discourses stem from the potential funding priorities 
based on the three causes which have been linked to breast cancer: genetics, life style 
choices, and environmental carcinogens.    Different actors and agencies join around 
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these two discourses and form the six advocacy coalitions who share similar core beliefs 
or discursive frames about what the research funding policies for breast cancer should be.  
These six coalitions are: 
 Coalition A: Research into Genetics 
 Coalition B: Research into Lifestyle Choices 
 Coalition C: Research into Screening Methods 
 Coalition D: Research into Medical Treatments 
 Coalition E: Research into the Environment 
 Coalition F: Research into Prevention 
Coalitions A through D represent the “actors” or agencies that share core beliefs or the 
discursive frame with the conventional discourse.  Coalitions E and F represent the 
alternative discourse and the agencies or actors who believe and represent the discursive 
frame that research funding policies are influenced by power and profit. 
The model on the next page visually represents the mechanism for research 
funding policies for breast cancer.  The two boxes on the left represent the two main 
discourses or discursive frames which may influence research funding policies for breast 
cancer.  These two main discursive frames represent the core beliefs of the various 
agencies and actors that join together to form the six advocacy coalitions- the middle two 
boxes.  These advocacy coalitions then testify in favor of or against the policies that are 
discussed during the congressional hearings, which leads to the eventual formation of the 
research funding policies for breast cancer (the box on the right).  
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Though the actors and agencies who testify or take part in the breast cancer hearings will 
be determined during the actual research phase of this study, there are several agencies 
and actors who may be expected to testify during breast cancer hearings: 
Agencies:  National Cancer Institute, American Cancer Society, Susan G. Komen 
Foundation, and the National Breast Cancer Coalition. 
Actors: The actors who testify will be the directors, presidents or CEOs of these 
agencies. 
 The remaining components of the ACF for breast cancer research funding policies are:  
 External subsystems: economic conditions and incident and mortality rates 
for the disease;  
 Relative stable parameters: such as the Cancer Act and the availability of 
resources.   
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All six of the coalitions compete to drive the policy process and form research funding 
policies for breast cancer. Figure P-6 on the next page depicts the ACF for breast cancer 
research funding policies.   
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Rationale for Using Congressional Hearings 
Though the ACF provides the framework for studying the policy process which 
determines researching funding activities for breast cancer; it does not define how to 
study the policy process.   In “Social Movements, Field Frames and Industry Emergence: 
a culture-political perspective on US Recycling”, Lousenbury and others examine how 
social movements work to impact institutional change and the creation of new industries.  
Recycling, which started as an environmental movement became mainstream and 
institutionalized (Lounsbury, 2003:71-104).  This paper explains how changes in policy 
or the views of institutions depend on infrastructure of existing networks, associations, 
organizations, and government.  Details are provided about how field frames are 
introduced, maintained, or changed in policy arenas such as Congressional hearings 
(Lounsbury, 2003:71-104).   
Congressional hearings provides a written record of the discussions about policy 
issues, the actors and agencies involved in these discussions and how all of these 
combined form or change policies.  These hearings provide a narrative text of the policy 
process discussion and the key actors that took part in this discussion to impact the 
creation or change of a policy (Lounsbury, 2003:71-104).  In order to better understand 
how the funding is determined during the congressional hearings, it is important to 
understand how Congress determines the federal budget and the steps involved in the 
budget process.  The budget process includes four phases (Dodd and Oppenheimer, 
1993:48-80): 
1) Preparation and submission of the budget by the President; 
2) Congressional action on the President’s proposed budget; 
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3) Execution of the budget related laws; 
4) Audit if agency spending.    
 
In order to address all four of these phases, Congress holds Authorization and 
Appropriation hearings in addition to normal policy related hearings.  The Authorization 
hearings determine the legislative issues or policies that require funding (Dodd and 
Oppenheimer, 1993:48-80).  The Appropriations hearings actually determine the amount 
funding that will be provide to each program.  Certain programs are automatically funded 
due to the fact that they are required by law, such as the NCI (Dodd and Oppenheimer, 
1993:48-80).  The congressional hearings, whether they are authorization or 
appropriations hearings, provide a written record of the agencies and actors who testified 
and the nature of their testimony.  The hearings for breast cancer will help determine this 
information so that the ACF can be utilized. 
Congressional hearings will provide the medium for using the ACF for policy 
analysis, in order to understand how and why breast cancer research funding policies set 
priorities for certain causes instead of others.  These hearings are not considered 
democratic, instead groups or agencies are invited to speak or they request to provide 
testimony.  Based on the topic and requests, decisions are made about who will testify 
and for how long.  The hearings provide Congress with information about certain policy 
topics and coalitions the opportunity to lobby for a particular cause (Miller, 2004; 
Svihula, 2007). 
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Major Findings 
This literature review has provided information about the epidemic of breast 
cancer in the United States.  The etiology, as well as the research details about the three 
causes for breast cancer has been provided.  The conflict between the research funding 
policies compared to the statistics on the actual causes of breast cancer has also been 
outlined.   This literature review has explained the disparities that exist between the 
actual causes of breast cancer and the ratio of funding these causes receive.   
Two discourses were identified that may explain the reasons for these disparities: 
the conventional and the alternative. These discourses were expanded by using social and 
policy theories about the role of power, market systems, and scientization of politics to 
explain how and why breast cancer research funding policies may be established and 
maintained.  
 
 
Major Gaps 
The major gap that has been identified from this literature review is that there 
seem to be funding disparities in breast cancer research activities.  In order to determine 
how and why these disparities exist, an analysis of the existing breast cancer funding 
policies needs to be conducted.  The ACF has been used to analyze policy processes for 
various environmental issues; however, it has not been used for studying the policy 
process for breast cancer research funding policies.   This dissertation purposes to apply 
the ACF and utilize the Congressional hearings for breast cancer research funding 
policies to determine if there is a systemic exclusion of research funding for certain 
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causes of breast cancer and if in fact there are power and market system forces which are 
driving the research funding decisions.   
 
Innovation and Significance 
 This research provides two levels of significance: theoretical and practical.  The 
theoretical innovation and significance of this work lies with utilizing the ACF and 
Congressional hearings to determine the role of environmental carcinogens on breast 
cancer causation.  Though the ACF has been utilized to analyze the policy process for 
other environmental policies, it has yet to be used to analyze the role of environmental 
causation of a disease.  This work will contribute to the current body of literature for the 
use of the ACF and provide an example of how Congressional hearings may be used to 
show power dynamics during the policy process. 
The practical significance of this work is that it will attempt to address the 
funding disparities for breast cancer and hope to shed light on how and why policies are 
determined and maintained.  This research will be able to make recommendations about 
the research policies and possibly impact the existing research funding policies to shift 
and be more inclusive of the role of environmental carcinogens on breast cancer 
causation.   
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CHAPTER 3: METHODS 
Overview 
 Chapter two provided the etiology of breast cancer; a glimpse into the current 
research funding policies for this disease; an explanation of the two main discourses and 
the associated six advocacy coalitions that explain how and why these research policies 
are determined; the theoretical framework; and a summary of the major findings and 
gaps.  The purpose of this chapter is to describe the methodology that was used.  There 
are four sections in this Chapter: research needs; research design; sampling rationale, data 
collection; and data processing and analysis.  
 
Research Needs 
Chapter two revealed that there is a disparity between the existing funding 
priorities and the causes of breast cancer. There is a need for research into funding 
policies for breast cancer to determine the reasons for the disparity.  There are many 
studies which identify the environmental carcinogens that are linked to breast cancer 
occurrence, but none that determine how and why the research funding policies do not 
focus on funding research activities for the environmental causes of breast cancer.   
In order to determine how and why research funding policies for breast cancer are 
formulated and if in fact these policies systematically exclude funding for the role of 
environmental carcinogens, this study applied theoretical arguments from sociology and 
utilize the Advocacy Coalition Framework (ACF). The ACF provided the adequate tool 
needed to conduct a thorough policy analysis on current breast cancer policies. 
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Research Objectives 
 The research objectives for this study were to determine: 
• If there are variations in the levels of advocacy for the different causes. 
• If these variations impact research funding levels.  
• If the amount differs by the advocacy coalition.  
• If there is a funding mismatch. 
Design 
This work utilized a qualitative approach, though quantitative data will be 
collected.  The research consisted of a cross-sectional design.  A cross-sectional design 
was used because each of the Congressional hearings represent one time period.    The 
overall approach will be a quantitative Content Analysis, which is the process of 
identifying, categorizing, and coding patterns of data in large amounts of textual 
information (Krippendorff, 2004; Patton, 371-389).  This study proposed to analyze 
Congressional hearings about research funding policies for breast cancer to determine 
how and why funding priorities are determined. Content analysis provided a means of 
conducting both qualitative and quantitative analysis.  The qualitative analysis was used 
to identify the predominant themes and the actors and agencies, hence the nature of the 
six coalitions.  The quantitative analysis was used to provide the data on the amount of 
time each coalition was given or not given to testify (the length of testimony).  
The literature identified two discourses which were linked to six advocacy 
coalitions that impact research funding decisions for breast cancer.  These two discourses 
are: conventional and alternative; and the six advocacy coalitions are: genetics, lifestyle 
choices, screening methods, medical treatments, environmental carcinogens, and 
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prevention.  It was determined that there could be multiple reasons for this research 
funding dynamic including: the culture or orientation of the agencies (NCI &ACS) 
charged with determining the research agendas; the training and knowledge of the experts 
setting the research agendas and actually conducting the research; and the involvement of 
advocacy and lobbying groups and the role they play in the agenda setting for research 
funding.  By using the ACF and conducting content analysis on Congressional hearings, 
it is hoped that reasons for how and why the research funding policies for breast cancer 
are determined. Depicted below is a model to be tested: 
      
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Advocacy Coalitions: 
Genetics                               
Lifestyle Choices                
Screening Methods                 
Medical Treatments       
Environmental Carcinogens 
Prevention 
Independent Variable: Extent 
of participation by the different 
advocacy coalitions  
Dependent Variable: Research 
funding policies for breast 
cancer. 
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The first hypothesis for this study was that research funding policies for breast 
cancer are driven by a policy process that is dominated by a combination of discursive 
coalitions which marginalize advocacy for research on the environmental causes of 
breast cancer. 
The null hypothesis is: Ho- All discursive coalitions have equal participation in 
the hearing process. 
The alternative hypothesis: Ha- The discursive coalition advocating research 
into the environmental causes of breast cancer is marginalized in the hearing process. 
 
The second hypothesis for this study was that the higher level of advocacy for 
non-environmental causes of breast cancer results in higher funding level for non-
environmental causes of breast cancer over environmental causes. 
  The null hypothesis is: Ho- Research Funding Priorities are not related to the 
different levels of discursive coalition participation in the hearing process. 
  The alternative hypothesis: Ha-   Research Funding Priorities are related to the 
different levels of discursive coalition participation in the hearing process. 
 
The third hypothesis for this study was that the economic interests of the 
presenter impacts the nature if the testimony for or against research funding on the 
environmental causes of breast cancer. 
  The null hypothesis is: Ho- The economic interests of the presenter does not 
impact the nature of the testimony. 
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  The alternative hypothesis: Ha-   The economic interests of the presenter do 
impact the nature of the testimony. 
 
Sampling Rationale, Data Collection 
Sampling Rationale: 
 Breast cancer has been a topic of Congressional hearings for several years.  The 
breast cancer movement came into governmental existence in 1990 with the passage of 
the Breast and Cervical Cancer Mortality Prevention Act.  Since then there have been 
approximately ten additional Acts about breast cancer and many associated 
Congressional hearings. A LexisNexis search revealed that there have been 128 
Congressional hearings that have included breast cancer as a topic.  Not all of these 
hearings, however, have dealt with issues relating to funding for research activities.  
Hence, the search for appropriate Congressional hearings for this study has to be 
narrowed to only included hearings that dealt specifically with appropriations for 
research funding policies for breast cancer.   
Therefore the sampling criterion for inclusion in this study was: Congressional 
hearings that dealt with appropriations for research funding activities only.  A modified 
LexisNexis search based on these criteria has identified 8 such Congressional Hearings; 
hence the sample size for this study will consist of these Congressional Hearings.   
Once these hearings were selected, they were coded using Atlas.ti.  In order to 
measure the research budget allocations, the budget data for the fiscal year following 
each of the hearings was collected from the United States Office of Management and 
Budget, NCI, and ACS to determine the allocations for particular research activities.  
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Variables 
 The independent variable for this study is: the extent of participation by the six 
advocacy coalitions defined below and the dependent variable is the research funding 
policies for breast cancer research: 
 
Genetics: Defined as the study of heredity; for the purposes of this study, refers 
to the evidence that there are “breast cancer genes” which seem to be responsible 
for causing breast cancer: the BRCA1 and the BRCA2 genes (Steingraber, 2000 
& Epstein 2003).   
Lifestyle Choices: defined as smoking, alcohol consumption, diet, exercise, 
reproductive behavior, and driven by cultural beliefs, and social status 
(Steingraber, 2000 & Epstein 2003).   
Screening Methods: Defined as tests and exams used to find breast cancer in 
people who do not have any symptoms; the three methods are breast self-exam, 
clinical breast exam, and mammograms (ACS, 2007).      
 
Medical Treatments: Defined as medical intervention for a disease; for breast 
cancer, the treatment options can involve removal of the tumor, removal of the 
breast, chemotherapy, radiotherapy, and other medications (ACS, 2007).   
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Environmental Carcinogens:  the environment, environmental pollutants and 
carcinogens that are considered as triggers for breast cancer causation (Epstein, 
2003, 2005).  Chemical pollutants produced by industrialization and are not the 
only environmental carcinogens, radiation and everyday items, such as cosmetics, 
pesticides, and household cleaning materials may also cause breast cancer (Brody, 
2005).  
 
Prevention: though usually associated with early detection and education about 
lifestyle choices; for the purpose of this study, prevention will be defined in 
relation to minimizing exposure to environmental carcinogens (Steingraber, 2000 
& Epstein 2003).   
 
Table P-1: Definition, Measurement and Source of Variables 
 
CONCEPT VARIABLE MEASURES SOURCE 
Extent of 
Participation 
of the 
different 
advocacy 
coalitions in 
congressional 
hearings 
1) Nature of the 
Discourse/Coalition:   
Genetics, Lifestyle 
Choices, Screening 
Methods, Medical 
Treatment, 
Environment, and 
Prevention 
 
1) Discourse/Coalition 
of Speaker:                
Genetics, Lifestyle 
Choices, Screening 
Methods, Medical 
Treatment, 
Environmental 
Carcinogens, and 
Prevention 
 
1) Coded from 
Congressional 
Hearing 
Extent of 
Participation 
of the 
different 
advocacy 
coalitions in 
2) Length of Testimony 2) Number of lines of 
testimony in the 
Congressional Record  
2) Coded from 
Congressional 
Hearing 
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congressional 
hearings 
The 
relationship 
between the 
economic 
interest (s) 
and the nature 
of the 
testimony 
3) Nature of the 
organization or 
advocacy of the 
presenter 
3) The mission of the 
organization and 
funding interests 
3) Coded from 
Congressional 
Hearing and the 
data from the 
organization’s 
website 
 
Research 
Allocations 
for Breast 
Cancer 
4) Breast Cancer 
Research budgets for 
NCI and ASC. 
4) Budget data 
following the fiscal 
year after the hearing  
4) Office of 
Management and 
Budget, NCI and 
ACS Annual 
Reports. 
 
 
Data Collection 
The specific Congressional hearings were downloaded from the US Government 
Printing Office in the appropriate format that is needed for the data analysis program.    
Once these hearings were identified, the following steps were utilized to conduct the 
research:  
1) Coded each Hearing- Atlas.ti and the coding sheet and instruction on  
the next page were used. 
2) The predominant themes of each coalition were identified; 
3) All of the information about each of the presenters and organizations 
which testified was identified and entered into an Excel spreadsheet; 
4) Descriptive and statistical analysis was conducted. 
 
Coding Instructions: For Congressional Hearings 
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 A separate coding sheet will be completed for each hearing.  Listed below are the 
codes and explanations for each characteristic:   
1) Hearing Characteristics: 
a. Title of the Hearing: as listed on the cover page 
b. Date of the Hearing: as listed on the cover page 
c. Name of the Committee that held the Hearing: as listed on the cover page 
d. Name of Chair Person presiding over the Hearing: as listed at the 
beginning of the Hearing 
e. State the chairperson represents: the initials of the state 
f. Party affiliation of the chairperson: 0- Democrat, 1- Republican, 2-Other 
2) Presenter Characteristics 
a. Name of presenter: as it appears at the beginning of the presentation 
b. Title or Position  
c. Education and Years of Experience 
d. Gender of Presenter 
e. Name of Organization they represent: as it appears at the beginning  
f. Type of Organization: 0- Government, 1-NGO, 2-Corporate/Industry, 3-
Advocacy, 
g. Type of NGO 
h. Nature of Advocacy 
i. Type of Business Interests of NGO 
j. Type of Corporation/Industry 
k. How long the presenter spoke: Count number of lines 
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l. Topic and content of presentation: 1-Genetics, 2-Lifestyle Choices, 3-
Screening Methods, 4-Medical Treatment, 5-Environment ,6-Prevention 
 
 
Coding Sheet for Breast Cancer Congressional Hearings 
 
Hearing Characteristics: 
Title of Hearing  
Date of Hearing  
Name of Committee   
Name of Chairperson  
State of Chairperson  
Party Affiliation: 0- Democrat 
                            1- Republican 
                            2- Other 
 
Presenter Characteristics 
Name of Presenter  
Title or Position  
Education and Years of Experience  
Gender of Presenter  
Name of Organization   
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
 
Type of NGO  
Nature of Advocacy  
Type of Business Interests of NGO  
Type of Corporation/Industry  
Length of Presentation  
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
 
Presenter Characteristics 
Name of Presenter  
Title or Position  
Education and Years of Experience  
Name of Organization  
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Gender of Presenter  
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
 
Type of NGO  
Nature of Advocacy  
Type of Business Interests of NGO  
Type of Corporation/Industry  
Length of Presentation  
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
 
Presenter Characteristics 
Name of Presenter  
Title or Position  
Education and Years of Experience  
Gender of Presenter  
Name of Organization  
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
 
Type of NGO  
Nature of Advocacy  
Type of Business Interests of NGO  
Type of Corporation/Industry  
Length of Presentation  
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
 
 
* The electronic coding sheet will continue until every presenter for each hearing is 
captured. 
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Validity and Reliability 
 
 There are issues that arise regarding validity and reliability with any social 
science research method.  Validity for content analysis involves insuring if in fact the 
inferences drawn from the documents can stand up to independent inferences and 
reliability involves data that is constant during the measuring process (Krippendorff, 
2004).  In order to achieve intercoder reliability and agreement: the coders must be 
selected from a population in which he/she is equally capable of being selected; each 
coder works independently; and that they utilize the same coding instructions 
(Krippendorff, 2004: 215-217).   
To insure that the coding scheme is free from ambiguity for this study, once the 
coding scheme was developed it was tested by two independent coders.  In keeping with 
Krippendorff’s rules above, the two independent coders were selected from a population 
of graduate students; they each independently coded one hearing; and they were provided 
with the same coding instructions.  Though the majority of the coding was 
straightforward for this study was very straightforward, the coding of the testimony could 
have been considered subjective; therefore two independent coders coded the same 
hearing to insure the level of agreement of the coding scheme.  The results are provided 
below:   
Hearing Characteristics: Coder 1 Coder 2 
Date of Hearing 7/21/1999 7/21/1999 
Name of Committee  Subcommittee on 
Health  & Environment 
Subcommittee on 
Health  & Environment 
Name of Chairperson Tom Bliley Tom Bliley 
State of Chairperson VA VA 
Presenter  1   
Name of Presenter Nancy Lee Nancy Lee 
Gender of Presenter Female Female 
Name of Organization  CDC CDC 
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Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
0 0 
Length of Presentation 121 121 
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
4 4 
Presenter  2   
Name of Presenter Fran Visco Fran Visco 
Gender of Presenter Female Female 
Name of Organization  National Breast Cancer  National Breast Cancer  
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
1 1 
Length of Presentation 91 91 
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
4 4 
Presenter  3   
Name of Presenter Susan Braun Susan Braun 
Gender of Presenter Female Female 
Name of Organization  Susan G. Komen Susan G. Komen 
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
1 1 
Length of Presentation 98 98 
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
4 4 
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               6-Prevention 
Presenter 4   
Name of Presenter Carloyn Tapp Carloyn Tapp 
Gender of Presenter Female Female 
Name of Organization  Women of Color B.C  Women of Color B.C  
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
1 1 
Length of Presentation 64 64 
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
4 4 
Presenter  5   
Name of Presenter Stanley Klausner Stanley Klausner 
Gender of Presenter Male Male 
Name of Organization  N/A N/A 
Type of Organization:  
               0- Government 
               1-NGO 
               2-Corporate/Industry 
               3-Advocacy 
N/A 3 
Length of Presentation 88 88 
Topic/Content of Presentation:  
               1-Genetics 
               2-Lifestyle Choices 
               3-Screening Methods 
               4-Medical Treatment 
               5-Environment 
               6-Prevention 
1 4 & 1 
 
 The hearing that was coded consisted of five testimonies and the two independent 
coders coded all but one of the testimonies the same.  Coder 1 rated the topic of the last 
testimony to be Genetics and Coder 2 rated the last testimony to be about Genetics and 
Medical Treatments.  There was at least 100% agreement between the two independent 
coders for all of the testimony but one, which was not even a full disagreement.   The 
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overall agreement between the two coders was 95%.  This coding scheme was also 
reviewed and approved by the Dissertation committee. Once the coding sheet was 
validated using these two methods, it was used for this study.   
 
Data Analysis 
 
The Atlas.ti software package was used to facilitate the Content Analysis and to 
assist with identifying the predominant themes in the testimony. Atlas.ti is a tool which 
provides for managing, organizing and supporting qualitative data.  It is considered to be 
a powerful tool for qualitative analysis of large bodies of textual data. It offers a variety 
of tools for coding of rich text and Word material and it can convert quantitative data to 
SPSS™ and coding tables to export into Excel™. 
 This software package provided the means to define the coding scheme and 
ability to analyze the hearings based on this coding scheme.  Once the testimony from 
each of the hearings was coded to identify the predominant themes, the total number of 
lines along with data about each of the presenters and organizations which testified was 
recorded in an Excel spreadsheet.  These spreadsheets were used to develop tables which 
assisted with the descriptive analysis. 
The data was also converted into SPSS version 16 and additional descriptive 
analysis was completed and the One Way Analysis of Variance (One Way ANOVA) and 
other statistical tests were used to test for significance for all three hypotheses. 
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CHAPTER 4: RESULTS & DISCUSSION 
Overview 
 Chapters one through three have provided an overview about the etiology of 
breast cancer; the current research funding policies for this disease; an explanation of the 
two main discourses and the associated six advocacy coalitions that explain how and why 
these research funding policies might be determined; the theoretical framework; and a 
summary of the major findings and gaps.  Chapter three also presented the methodology 
that was used; the research needs; research design; sampling rationale, data collection; 
and data processing and analysis. The purpose of this chapter is to describe and discuss 
the results from the content analysis of the Congressional hearings.  This chapter includes 
four sections: the purpose of the study; hypotheses; data analysis; and summary of 
results. 
Purpose of the Study 
There are many studies which have identified environmental carcinogens as 
potential causative agents for breast cancer; but none of the studies has explained why 
research funding polices for breast cancer do not focus on funding research activities for 
the environmental causes of breast cancer.  The literature review from Chapter two 
revealed that there seems to be a disparity between the existing research funding 
priorities and the causes of breast cancer and the need for research into how and why this 
disparity exists.  In order to determine how and why research funding policies for breast 
cancer are formulated and if in fact these policies systematically exclude funding for the 
role of environmental carcinogens on breast cancer causation, this study applied the 
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theoretical arguments from sociology and utilized the Advocacy Coalition Framework 
(ACF) to conduct a thorough policy analysis of research funding policies for breast 
cancer.   
This research was conducted to answer several questions: 
• How the research funds are being spent and why certain causes receive 
more research funding while other causes are not funded? 
• Why there is a funding mismatch between the causes and research 
activities being funded? 
• Are there variations in the levels of advocacy for the different causes? 
• Do these variations impact research funding levels? 
• Are the levels of advocacy determining research priorities for funding? 
In order to best answer the above questions, the hypotheses must be addressed 
individually.  The three hypotheses for this study are reiterated in the next section and 
they will be addressed first by the qualitative analysis of each of the Congressional 
hearings, followed by the quantitative analysis to determine if in fact the data supports 
the null or the alternative hypotheses. 
Hypotheses 
The first hypothesis for this study was that research funding policies for breast 
cancer are driven by a policy process that is dominated by a combination of discursive 
coalitions that marginalize advocacy for research on the environmental causes of 
breast cancer. 
* Various agencies and actors join together to form the six advocacy coalitions which stem from the two main 
discourses or discursive frames (conventional or alternative).   
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The null hypothesis is: Ho- All discursive coalitions have equal participation in 
the hearing process. 
The alternative hypothesis: Ha- The discursive coalition advocating research 
into the environmental causes of breast cancer is marginalized in the hearing process. 
 
The second hypothesis for this study was that the higher level of advocacy for 
non-environmental causes of breast cancer results in higher funding level for non-
environmental causes of breast cancer over environmental causes. 
  The null hypothesis is: Ho- Research Funding Priorities are not related the 
different levels of discursive coalition participation in the hearing process. 
  The alternative hypothesis: Ha-   Research Funding Priorities are related to the 
different levels of discursive coalition participation in the hearing process. 
 
The third hypothesis for this study was that the economic interests of the 
presenter impacts the nature if the testimony for or against research funding on the 
environmental causes of breast cancer. 
  The null hypothesis is: Ho- The economic interests of the presenter does not 
impact the nature of the testimony. 
The alternative hypothesis: Ha-   The economic interests of the presenter do 
impact the nature of the testimony. 
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Qualitative Analysis of Each Hearing 
As mentioned in Chapter three, the breast cancer movement came into 
governmental prominence in 1990 with the passage of the Breast and Cervical Cancer 
Mortality Prevention Act. Since that time there have been many Congressional hearings 
devoted to the topic of breast cancer.  These hearings have covered issues associated with 
insurance coverage for certain procedures, the need for a breast cancer stamp, and 
funding for research activities.  Due to the fact that this study focused only on funding 
policies for research activities, the sampling criteria for inclusion in this study were: 
Congressional hearings which addressed research funding and activities for breast cancer.  
A modified LexisNexis search based on this criterion identified 8 such Congressional 
hearings that were available in print; hence the sample size for this study consisted of 
these Congressional hearings.  A coding sheet was developed to be utilized for the 
Content Analysis and tested by two independent coders to ensure validity of the coding 
sheet.  The coding sheet was adjusted to also include feedback from the dissertation 
committee.  The results for each of the 8 hearings are as follows. 
 
 
 
 
Hearing # 1: The Role of Early Detection and Complementary and Alternative Medicine 
in Women’s Cancers 
 
 This hearing was held on August 10, 1999 before the Committee on Government 
Reform.  The hearing was held to determine if there were alternative medicines for use in 
treating cancers, including breast cancer and funding for appropriate research activities.  
The qualitative analysis determined that the predominant coalitions and discourses 
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represented were the screening methods and medical treatment.  Nine people were invited 
to testify, five of which were women and Table P-2 below summarizes the coding results 
of the testimony: 
Table P-2 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
 
 
 
Presenter Title/ 
Position 
Education Gender Organization  Organization 
Type 
Discourse/Advo
cacy Coalition  
Priscilla 
Mack 
Executiv
e Co-
Chair 
N/A Female Susan G. Koman  
1            3 , 4 
Michio 
Kushi 
N/A N/A Male Kushi Institute 
1 2  
Carol 
Zurycki 
N/A   Female Advocate 
3 5, 6  
Lee Garden N/A PhD Female Advocate 3 6  
Linda L 
Bedell 
Logan 
President
/CEO   Female 
Solutions 
Integrative 
Medicine 2 4 ,6  
James 
Gordon Founder MD Male 
Center for Mind 
Body Medicine 3 2  
Susan Silver N/A N/A Female 
George 
Washington 
University 3 2 ,3  
Dan Beilin 
Research
er PhD, MD Male UCLA 3 3  
Edward 
Trimble 
Head of 
Surgery MD Male NCI 0 1 ,3,4  
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Hearing # 2: Making Sense of the Mammography Controversy: What Women Need to 
Know 
 
 This hearing was held on February 28, 2002 in front of the Subcommittee on 
Public Health of the Committee on Health, Education, Labor, and Pensions.  Six people 
were invited to testify and only two were women.  The predominant themes of the 
coalitions which testified and the discourses represented were medical treatments and 
screening methods.  Table P-3 below summarizes the coding results of the testimony: 
 
Table P-3 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
Presenter Title or 
Position 
Education Gender Organization Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Andrew Von 
Eschenbach Director MD Male NCI 0 3, 4 
Donald Berry Chairman MD Male 
Anderson 
Cancer Center 2 3,4  
Harman Eyre 
Chief 
Medical 
Officer MD Male ACS 1 3, 4  
Fran Visco President Lawyer Female 
National 
Breast Cancer 
Coalition 1 3 ,4 , 5  
Carolyn 
Runowicz 
Vice-
Chairman MD Female 
St.Lukes 
Roosevelt 
Hospital 2 3 ,4  
Lasalle D. 
Leffall 
Chairman-
Elect MD, FACS Male 
Susan 
G.Komen 1 3,4  
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Hearing # 3: Breast and Cervical Cancer Federally Funded Screening Programs 
 
 
 This hearing was held on July 21, 1999 in front of the Subcommittee on Health 
and Environment of the Committee on Commerce.  Five people were invited to testify, of 
which four were women.  The predominant themes of the advocacy coalitions 
represented at this hearing were screening methods and medical treatment and Table P-4 
below summarizes the coding results of the testimony: 
 
Table P-4 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
Presenter Title or 
Position 
Education Gender  Organization Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Nancy Lee 
Director-
Cancer 
Prevention MD Female CDC 0 3,4  
Fran 
Visco President Lawyer Female 
National 
Breast Cancer 
Coalition 1 3 , 4, 6 
Susan 
Brawn 
President & 
CEO N/A Female 
Susan 
G.Komen 1 3 , 4 
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Carolyn 
Tapp President N/A Female 
Women of 
Color Breast 
Cancer 3 4  
Stanley 
Klausner 
Surgeon/Dir
ector MD Male 
Brookhaven 
Memorial 
Hospital 3 3 , 4  
 
 
 
 
Hearing # 4: Cancer Clusters in Long Island, NY 
 
 This hearing was held on June 11, 2001 in front of the Committee on 
Environment and Public Works.  Twelve people were invited to testify, seven were 
women, and the predominant theme of this hearing was about the environmental causes 
of breast cancer and the dominant advocacy coalition was the environment.  In fact this 
hearing was convened to support the creation the Breast Cancer and Environmental 
Research Act. This Act would have established research activities that were geared 
towards gaining better understanding about what links between the environment and 
breast cancer may exist, and would have authorized funding to the National Institute of 
Environmental Health Sciences (NIEHS) to establish multidisciplinary, multi-
institutional research centers to study these potential links. Table P-5 summarizes the 
coding results of the testimony: 
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Table P-5 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
 
Presenter Title or 
Position 
Education Gender Organization Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Gail Frankel 
Field 
Coordinator N/A Female 
National 
Breast Cancer 
Coalition 3 5  
Marlie 
Gamman 
Associate 
Professor PhD Female 
SPH- Chapel 
Hill NC 3 5  
Lynn 
Glodman Professor MD, MPH Female 
Johns Hopkins 
SPH 3 5  
Richard 
Jackson Director MD, MPH Male CDC- NCEH 0 5  
Amy Juchatz 
Health 
Program 
Analyst N/A Female 
Suffolk 
County Health 0 5  
Phil 
Landrigan 
Professor/ 
Chair MD, MSC Male 
MtSinia 
Sch.Medi 3 5  
Karen Joy 
Miller 
Founder/ 
President N/A Female 
NY Breast 
Cancer Action 
Coalition 3 5,6 
Ruby Seni Professor PhD Female 
Mailman SPH- 
Columbia 3 5  
Tim Tobin Parent N/A Male N/A 3 5  
Randall Todd 
State 
Epidimiogist MD Male 
Nevada State 
Health 0 5  
Deborah 
Winn 
Acting 
Associate 
Director PhD Female NCI 0 1, 5 
Samual 
Wilson 
Deputy 
Director MD Male 
National 
Institute of 
Environmental 
Health 0 1,2,5 
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Hearing # 5: Tamoxifen and Breast Cancer 
 
 This hearing was held in 1998 in front of the Senate Committee on 
Appropriations. Six people were invited to testify, only two were women, and the 
predominant advocacy coalitions that testified were genetics, screening, and medical 
treatments. Table P-6 below summarizes the coding results of the testimony: 
 
Table P-6 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
 
 
 
 
 
Presenter Title or 
Position 
Education Gender  Organization Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Harold 
Varmus Director MD Male NIH 0 2,4 
Norman 
Wolmark Chairman MD Male 
National 
Surgical 
(NSABP)- 
NCI 1 4 
Richard 
Klausner Director MD Male NCI 0 1, 4 
Helen Wilson 
Clinical 
Trial 
Manager RN Female Merk 3- Pharmaceutical 4 
Cynthia 
Pearson 
Executive 
Director   Female 
National 
Women's 
Health 
Network 3 6 
Bernard 
Fisher Chairman MD Male 
National 
Surgical 
(NSABP)- 
NCI 3 1,3,4  
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Hearing # 6: Women and Cancer: Where Are We in Prevention, Early Detection and 
Treatment of Gynecologic Cancers? 
 
 
 This hearing was held on September 7, 2005 in front of the Subcommittee on 
Criminal Justice, Drug Policy, and Human Resources of the Committee on Government 
Reform.  This hearing focused on determining how early detection and medical 
treatments can impact cancers, specifically breast cancer.  The predominant advocacy 
coalitions that testified were genetics, lifestyle choices, screening methods and medical 
treatment.  Seven people were invited to testify, three were women, and Table P-7 below 
summarizes the coding results of the testimony: 
Table P-7 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening 
Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
Presenter Title or Position Education Gender Organization  Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Beth 
Kartan President MD Female 
Society of 
Gynecologic 
Oncologists 3 1,2,4,6 
Mark Jay 
Rosenfeld Scientist/Researcher MD Male 
Research/Advo
cacy 3 3 
Sheryl 
Silver 
President/ Johanna's 
Law N/A Female Foundation 1 3 
Kolleen 
Stacey N/A N/A Female Survivor 3 3,4,6 
Edward 
Trimble Head of Surgery MD Male NCI 0 3, 4 
Edward 
Thompson 
Chief of Public 
Health Practice MD, MPH Male CDC 0 2,3,4 
Richard 
Pazer Director MD Male FDA 0 4 
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Hearing # 7: Mammography  
 
 This hearing was held on February 5, 1997 in front Senate Committee on 
Appropriations.  The hearing was convened to review the role of mammography 
programs as a means for reducing morbidity and mortality from breast cancer.  Eight 
people were invited to testify, four were women, and Table P-8 below summarizes the 
coding results of the testimony: 
 
Table P-8 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-
Screening Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
Presenter Title or 
Position 
Education Gender Organization  Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Richard 
Klausner Director MD Male NCI 0 3 
Susan 
Blumenthal 
Deputy Asst. 
Secretary MD, MPA Female US Surgeon General 0 3 
Fran Visco President Lawyer Female 
National Breast 
Cancer Coalition 1 3, 6 
Susan 
Brawn President N/A Female Susan G.Komen 1 3 
Diana 
Rowden Chair N/A Female Susan G.Komen 1 3 
Ann M. 
Leitch 
Assosciate 
Professor MD Female 
University of Texas 
Med. Sch. ACS 3 3, 4 
Barbara 
Monsees 
Assosciate 
Professor MD Female 
St.Louis Med. Sch.- 
ACS 3 3 
David G. 
Hoel 
Professor/Cha
ir PhD Male 
Hollings Cancer 
Center- NIH 3 3, 4 
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Hearing # 8: Breast Cancer Research and Development 
 
 
 This hearing was held on May 9, 2001 in front Senate Committee on 
Appropriations. The hearing was convened to determine the current research activities 
funded for breast cancer. Eight people were invited to testify, four were women, and 
Table P-9 below summarizes the coding results of the testimony: 
 
Table P-9 
The numbers in the Tables represent: 
Type of Organization:   0- Government, 1-NGO, 2-Corporate/Industry, 3-Advocacy; 
Discourse/Advocacy Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-
Screening Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
Presenter Title or 
Position 
Education Gender  Organization  Organization 
Type 
Discourse/ 
Advocacy 
Coalition 
Richard 
Klausner Director MD Male NCI 0 1,,2, 3 ,4 
James 
Marks Director MD, MPH Male CDC 0 3, 4 
Nancy 
Brinker Chairman N/A Female Susan G.Komen 1 3, 4 
Christine 
Carpenter Member Masters Female 
National Breast 
Cancer Coalition 1 3, 4 
Peri Giplin Actress   Female 
National Breast 
Cancer Coalition 1 3, 4 
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Lasalle D. 
Leffall 
Chairman-
Elect 
MD, 
FACS Male Susan G.Komen 1 3, 4 
John Seffrin CEO MD Male ACS 1 3, 4 
Fran Visco President Lawyer Female 
National Breast 
Cancer Coalition 1 3,4,5,6 
 
 
Quantitative Analysis of the Hearing Data 
The qualitative analysis has provided very descriptive and detailed information 
for each of the hearings.  The analysis has provided very specific information about the 
agencies and actors that testified and the discourse advocacy coalitions they represented 
during their testimony; along with information about the gender and educational 
background for each of the presenters/actors.  Though this qualitative analysis has 
provided very rich and detailed information about the hearings, quantitative analysis has 
to be conducted to test for significance and to determine if the qualitative analysis mirrors 
the quantitative analysis.     
In order to perform the appropriate quantitative analysis and accurately test each 
of the hypotheses, the data for the following variables had to be collapsed into binary 
variables:  discourse, presenter’s interest, and research funding.  These three variables 
originally had values that were too specific leading to very small “n’s” and therefore any 
statistically significant value would have to be interpreted with caution.  For these 
reasons, it was decided that the discourse variable (advocacy coalition) would be 
separated into two categories: individual (the internal) and the environment (external).  
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The original six advocacy coalition categories were collapsed into- 1= Individual- which 
included testimony about Genetics, Lifestyle Choices, Screening Methods, Medical 
Treatments, and Prevention; and 2= Environment- which included testimony about the 
environmental carcinogens.  The presenter’s interest variable was collapsed into: 
1=economic interest, the presenter/actor or presenter’s agencies seeking funding; and 2= 
no economic interest, the presenter/actor not seeking funding.  The research funding 
variable was collapsed into 1=funded research activities and 2= not funded. 
 Descriptive Analysis 
A total of 8 hearings were coded for this study.  Sixty-one testimonies were 
presented during these hearings and the number of testimonies per hearing ranged from 5 
presenters in Hearing # 3 to 12 presenters in Hearing # 4.  Fifty-three unique individuals 
presented these 61 testimonies, with several individuals testifying at more than one 
hearing. Dr. Lasalle D.Leffall and Susan Brawn both representing, the Susan G. Komen 
Foundation, testified at two different hearings; Dr. Edward Trimball and Dr.Richard 
Klausner, both representing the NCI, testified a total of five times; and Fran Visco, an 
attorney and the founder of the National Breast Cancer Coalition, testified four times. Of 
the 61 testimonies, 42.6% consisted of testimony regarding a single advocacy coalition 
discourse; 41.0 % testified for two advocacy coalitions, 11.5% presented three, and 4.9% 
testimonies included four advocacy coalitions in their testimony. 
There were slightly more female presenters than male (54.7% vs. 45.3%).  There 
was no significant difference in the number of lines or percentage of lines testimony by 
gender. The educational background of the presenters consisted of 49.1 % MDs, 11.3% 
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were PhDs, and 32.1% did not have a graduate or professional degree.  These presenters 
were survivors, film actors, and parents of survivors.  The average percentage of lines of 
testimony by education was also not significantly different. 
 Of all of the testimony presented, nearly two-thirds advocated for the following 
coalitions: screening methods, medical treatment, and environment.  When the hearing 
that was dedicated to environmental issues (hearing # 4) was removed from the analysis, 
the predominant coalitions represented at all of the hearings were the Screening Methods 
and Medical Treatment coalitions.  More than half of the presenters were associated with 
organizations that represent medical and research institutions, universities, and 
foundations which fundraise for breast cancer.  The main organization types represented 
were: NGOs (43.4 %) which receive funding from the government and donations; the 
government agencies which distribute grant funds for research (26.4%); and advocacy 
groups (24.5%), which consisted of survivors or have family members impacted by the 
disease.  There were a few presenters who represented business and industry, mainly the 
pharmaceutical companies and cancer treatment facilities.  
Hypothesis Testing 
 Due to the fact that this study has a small sample size, small sample statistics were 
utilized.  The statistical analysis consisted of analysis of variance (One Way ANOVA), 
Independent t-tests, and cross tabulations.  The first hypothesis for this study was that 
research funding policies for breast cancer are driven by a policy process that is 
dominated by a combination of discursive coalitions that marginalize advocacy for 
research on the environmental causes of breast cancer. 
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Figure P-7 is a graph depicting the coalition and the total number of lines of 
testimony by coalition for all 8 hearings.  The graph has two bars, with the blue bar 
representing the analysis with the Environmental hearing included and the burgundy bar 
representing the analysis with the Environmental hearing (hearing # 4) excluded.  The 
Screening Methods and Medical Treatment coalitions had the most amount of testimony, 
regardless of whether the Environmental hearing was included or excluded.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure P-7: Coalition Participation for all Congressional Hearings 
 
 
Though the descriptive analysis regarding the percent of testimony being higher 
for Screening Methods and Medical Treatments may suggest the marginalization of the 
other advocacy coalitions, the statistical analysis showed no significant difference in the 
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percent of lines of testimony by advocacy coalition/discourse, even with the 
Environmental hearing removed, hence the alternative hypothesis Ha- “The discursive 
coalition advocating research into the environmental causes of breast cancer is 
marginalized in the hearing process”, must be rejected and the null hypothesis is: Ho- 
“All discursive coalitions have equal participation in the hearing process”, would be 
accepted. 
The second hypothesis for this study was that the higher level of advocacy for  
non-environmental causes of breast cancer results in higher funding level for non-
environmental causes of breast cancer over environmental causes.  Table P-10 represents 
the hearing, the year of the hearing, the dominant testimony based on the advocacy 
coalition with the most number of lines and the percentage of testimony devoted to the 
advocacy coalition, and the funded research activities from the appropriations for the NCI 
budget for the fiscal year following the hearing and the ACS budget for research 
activities for this same time period.  
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Table P-10 
 
 
The numbers in the Tables represent: 
Discourse/Coalition of Presentation: 1-Genetics, 2-Lifestyle Choices, 3-Screening Methods, 
4-Medical Treatment, 5-Environment, 6-Prevention 
Research Activities Funded: 1-Genetics, 2-Lifestyle Choices, 3-Screening Methods, 
4-Medical Treatment, 5-Environment, 6-Prevention 
 
 
 
Dominant Testimony Advocacy Coalitions  Hearing 
# 
Year of 
Hearing # of Lines % (# of lines for 
discourse/total # of 
lines) 
Discourse of 
Funded Research 
Activities 
1 1999 1- 111; 2 -428 lines; 
3-244.5 lines; 4-285; 
5-76 lines; 6-340 lines 
1- 7.1%; 2 -27.3%; 3-
20.8%; 4-18.2%; 5-
4.8%; 6-21.7% 
1, 2, 3, 4 
2 2002 3 - 850 lines; 4 -849 
lines; 5- 99 lines 
3-47.3%; 4 -47.2%; 
5-5.5% 
1, 2, 3, 4 
3 1999 3- 451 lines; 4-562 
lines; 6- 95 lines 
3-40.7%; 4-50.7%; 6-
8.6% 
1, 2, 3, 4 
4 2001 1- 27 lines; 2-29 lines; 
5- 848 lines; 6-51 
lines 
1- 2.6%; 2-2.7%s; 5-
80.3%; 6-4.8% 
1, 2, 3, 4 
5 1998 1 -103 lines; 2 -24 
lines; 3- 17 lines; 4- 
542 lines; 6-150 lines 
1 -12.4%; 2 -2.9%; 3-
2 %; 4-65%; 6-18% 
1, 2, 3, 4 
6 2005 1 -34 lines; 2 -94 
lines; 3- 267 lines; 4- 
227 lines; 6-57 lines 
1 -5%; 2 -13.8%; 3-
39.3%, 4- 33.4%; 6-
8.4% 
1, 2, 3, 4 
7 1997 3 - 1330 lines; 4 -172 
lines; 6- 61 lines 
3 – 85.1%; 4 -11%; 6-
4% 
1, 2, 3, 4 
8 2001 1 -123 lines; 2 -123 
lines; 3- 643 lines; 4- 
644 lines; 5- 32 lines; 
6-57 lines 
1 -7.7%; 2 -7.7%; 3- 
40%; 4- 40.1%; 5- 
2%; 6-3.5% 
1, 2, 3, 4 
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Based on this table, it can be seen that for all but one of the hearings, the 
advocacy coalitions which testified and had the greater number of lines or higher 
percentage of testimony (in bold text) received funding for research activities.  Hearing # 
4 is the only exception to this finding, though the Environmental Advocacy Coalition had 
the most lines of testimony, there was no impact on the funding for research activities.  A 
review of the fiscal year budgets for NCI and ACS revealed that though the overall 
funding for research activities for breast cancer has increased over the years; there have 
been no changes in the coalitions being funded for research activities.  The bulk of the 
funding continues to support research activities that are represented by the Genetics, 
Lifestyle Choices, Screening Methods, and Medical Treatments.   
The statistical analysis for hypothesis two showed no statistically significant 
difference in the percent of lines of testimony and research funding (t=1.75, p=0.082), 
therefore the null hypothesis “research funding priorities are not related to the different 
levels of discursive coalition participation in the hearing process.” would be accepted.  
The third hypothesis for this study stated that the economic interests of the 
presenter impacts the nature if the testimony for or against research funding on the 
environmental causes of breast cancer.  This hypothesis speaks to the notion that research 
funding decisions are based on profit and that the coalitions which testify at the hearings 
are driven by economic interests rather than science.  The table P-11 provides the results 
from the content analysis and gives insight into the presenter, the organization, the 
mission of the organization, the advocacy coalition, and the research activities the 
organization supports. 
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Table P-11 
The numbers in the Tables represent: Presenter’s Coalition of Interest: 1-Genetics, 2-Lifestyle 
Choices, 3-Screening Methods, 4-Medical Treatment, 5-Environment, 6-Prevention 
Research Activities Funded: 1-Genetics, 2-Lifestyle Choices, 3-Screening Methods, 4-Medical 
Treatment, 5-Environment, 6-Prevention 
 
 
 
Hearing # 1 
Presenter Organization  Organization Mission Presenter’s 
Interests  
Research  
Activities 
Funded 
Priscilla 
Mack 
Susan G. Komen  We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3, 4 
1, 2, 3, 4 
Michio 
Kushi 
Kushi Institute Our Mission is to teach, guide 
and inspire individuals 
towards greater personal 
freedom, health, happiness and 
peace by using the principles 
of Kushi Macrobiotics. 2 
2 
Carol 
Zurycki 
Advocate 
Not Available 5,6 
N/A 
Lee 
Garden 
Advocate 
Not Available 6 
N/A 
Linda L 
Bedell 
Logan 
Solutions 
Integrative 
Medicine Not Available 4,6 
4 
James 
Gordon 
Center for Mind 
Body Medicine Not Available 2 
2 
Susan 
Silver 
George 
Washington 
University 
Teaching with creativity and 
dedication, Healing with 
quality and compassion, 
Discovering with imagination 
and innovation. 2,3 
1, 2, 3, 4 
Dan 
Beilin UCLA  3 
1, 2, 3, 4 
Edward 
Trimble NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 1,3,4 
1, 2, 3, 4 
Hearing # 2 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Andrew 
Von 
Eschen-
bach NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 3,4 
1, 2, 3, 4 
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agency for cancer research and 
training 
Donald 
Berry 
Anderson Cancer 
Center 
Our mission is simple – to 
eliminate cancer. Achieving 
that goal begins with 
integrated programs in cancer 
treatment, clinical trials, 
education programs and 
cancer prevention. 3,4 
1, 2, 3, 4 
Harman 
Eyre ACS 
The American Cancer Society 
is the nationwide community-
based voluntary health 
organization dedicated to 
eliminating cancer as a major 
health problem by preventing 
cancer, saving lives, and 
diminishing suffering from 
cancer, through research, 
education, advocacy, and 
service. 3,4 
1, 2, 3, 4 
Fran 
Visco 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  3,4,5,6 
N/A 
Carolyn 
Runowicz 
St.Lukes 
Roosevelt 
Hospital 
Established in 1871, St. 
Luke's-Roosevelt Hospital 
Center, University Hospital of 
Columbia University College 
of Physicians and Surgeons, is 
a 1,076-bed, full-service 
community and tertiary care 
hospital. 3,4 
1, 2, 3, 4 
Lasalle D. 
Leffall Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3,4 
1, 2, 3, 4 
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Hearing # 3 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Nancy 
Lee CDC 
To direct, monitor, and report 
on activities associated with 
the implementation of the 
Breast and Cervical Cancer 
Mortality Prevention Act of 
1990, Public Law 101-354 and 
the Cancer Registries 
Amendment Act, Public Law 
102-515. 3,4 
1, 2, 3, 4 
Fran 
Visco 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  3,4,5,6 
N/A 
Susan 
Brawn Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3,4 
1, 2, 3, 4 
Carolyn 
Tapp 
Women of Color 
Breast Cancer 
Provide psychosocial for you 
and your loved ones; Provide 
crisis intervention for you and 
your loved ones; Provide 
breast health education to 
community members at large; 
Offer knowledge focused on 
early detection; Commit to 
effecting public policy; 
Commit to social change 
regarding breast health 
awareness; Support culturally 
sensitive research; Lobby on 
both state and federal levels 
for breast cancer legislation  4 
2 
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Stanley 
Klausner 
Brookhaven 
Memorial 
Hospital 
Deliver accessible, high-
quality health services in a 
focused caring environment 
while providing health 
advocacy for the community 
and people we serve. 3,4 
1, 2, 3, 4 
Hearing # 4 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Gail 
Frankel 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  5 
1, 2, 3, 4 
Marlie 
Gamman 
SPH- Chapel 
Hill NC 
The School's mission is to 
improve public health, 
promote individual well-being 
and eliminate health 
disparities 5 
1, 2, 3, 4 
Lynn 
Glodman 
John's Hopkins 
SPH 
The Johns Hopkins 
Bloomberg School of Public 
Health is dedicated to the 
education of a diverse group 
of research scientists and 
public health professionals, a 
process inseparably linked to 
the discovery and application 
of new knowledge, and 
through these activities, to the 
improvement of health and 
prevention of disease and 
disability around the world. 5 
1, 2, 3, 4 
Richard 
Jackson 
CDC- National 
Env. Cent. 
The National Center for 
Environmental Health plans, 
directs, and coordinates a 
national program to maintain 
and improve the health of the 5 
1, 2, 3, 4 
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American people by 
promoting a healthy 
environment and by 
preventing premature death 
and avoidable illness and 
disability caused by non-
infectious, non-occupational 
environmental and related 
factors. 
Amy 
Juchatz 
Suffolk County 
Health 
The mission of the Suffolk 
County Department of Health 
Services is to assure the well-
being of the community by 
preventing disease, promoting 
healthy behavior and 
preserving the health of our 
residents. 5 
1, 2, 3, 4 
Phil 
Landrigan 
MtSinia 
Sch.Medi 
Commitment to excellence in 
research, education, and 
patient care form the 
foundation that makes Mount 
Sinai School of Medicine 
(MSSM) in Manhattan one of 
the world’s foremost centers 
for medical and scientific 
training. 5 
1, 2, 3, 4 
Karen Joy 
Miller 
NY Breast 
Cancer Action 
Coalition 
Our mission is to focus on 
prevention methods while 
actively helping those who are 
faced with a positive 
diagnosis. 5,6 
N/A 
Ruby Seni 
Mailman SPH- 
Columbia Not Available  5 
N/A 
Tim Tobin N/A Not Available  5 N/A 
Randall 
Todd 
Nevada State 
Health Not Available  5 
N/A 
Deborah 
Winn NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 1,5 
1, 2, 3, 4 
Samual 
Wilson 
National Institute 
of 
Environmental 
Health 
The mission of the NIEHS is 
to reduce the burden of human 
illness and disability by 
understanding how the 
environment influences the 
development and progression 
of human disease. 1,2,5 
1, 2, 3, 4 
Hearing # 5 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Harold 
Varmus NIH 
NIH is the steward of medical 
and behavioral research for the 2, 4 
1, 2, 3, 4 
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Nation. Its mission is science 
in pursuit of fundamental 
knowledge about the nature 
and behavior of living systems 
and the application of that 
knowledge to extend healthy 
life and reduce the burdens of 
illness and disability 
 
Norman 
Wolmark 
National 
Surgical 
(NSABP)- NCI 
The NSABP pioneered breast 
cancer studies that have led to 
the establishment of 
lumpectomy plus radiation 
over radical mastectomy as the 
standard surgical treatment of 
breast cancer 4 
 2, 3, 4 
Richard 
Klausner NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 
 1, 4 
1, 2, 3, 4 
Helen 
Wilson Merk 
The mission of Merck is to 
provide society with superior 
products and services by 
developing innovations and 
solutions that improve the 
quality of life and satisfy 
customer needs, and to 
provide employees with 
meaningful work and 
advancement opportunities, 
and investors with a superior 
rate of return. 4 
 3, 4 
Cynthia 
Pearson 
National 
Women's Health 
Network 
The National Women's Health 
Network improves the health 
of all women by developing 
and promoting a critical 
analysis of health issues in 
order to affect policy and 
support consumer decision-
making. The Network aspires 
to a health care system that is 
guided by social justice and 
reflects the needs of diverse 
women. 
 6 
1, 2, 3, 4 
Bernard 
Fisher 
National 
Surgical 
(NSABP)- NCI 
The NSABP pioneered breast 
cancer studies that have led to 
the establishment of 
lumpectomy plus radiation 
over radical mastectomy as the 
standard surgical treatment of 
breast cancer 1,3,4 
1, 2, 3, 4 
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Hearing # 6 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Beth 
Kartan 
Society of 
Gynologic 
Oncologists 
The purpose of SGO is to 
improve the care of women 
with gynecologic cancers by 
encouraging research and 
disseminating knowledge to 
raise the standards of practice 
in the prevention and 
treatment of gynecologic 
malignancies, in cooperation 
with other organizations 
interested in women's health 
care, oncology and related 
fields. 1,2,4,6 
1, 2, 3, 4 
Mark Jay 
Rosenfeld 
Research/Advoc
acy Not Available 3 
N/A 
Sheryl 
Silver Foundation Not Available 3 
N/A 
Kolleen 
Stacey Survivor Not Available 3,4,6 
N/A 
Edward 
Trimble NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 3,4 
1, 2, 3, 4 
Edward 
Thompson CDC 
To promote health and quality 
of life by preventing and 
controlling disease, injury, and 
disability. 2,3,4 
1, 2, 3, 4 
Richard 
Pazer FDA 
The FDA is responsible for 
protecting the public health by 
assuring the safety, efficacy, 
and security of human and 
veterinary drugs, biological 
products, medical devices, our 
nation’s food supply, 
cosmetics, and products that 
emit radiation. The FDA is 
also responsible for advancing 
the public health by helping to 
speed innovations that make 
medicines and foods more 
effective, safer, and more 
affordable; and helping the 
public get the accurate, 
science-based information 
they need to use medicines 
and foods to improve their 
health. 4 
2,3,4 
Hearing # 7 
Presenter Organization  Organization Mission Presenter’s Research  
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Interests Activities 
Funded 
Richard 
Klausner NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 3 
1, 2, 3, 4 
Susan 
Blumen-
thal 
US Surgeon 
General 
The Surgeon General serves as 
America's chief health 
educator by providing 
Americans the best scientific 
information available on how 
to improve their health and 
reduce the risk of illness and 
injury. 3 
1, 2, 3, 4 
Fran 
Visco 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  3,6 N/A 
Susan 
Brawn Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3 
1, 2, 3, 4 
Diana 
Rowden Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3 
1, 2, 3, 4 
Ann M. 
Leitch 
University of 
Texas Med. Sch. 
ACS 
Not Available 
3,4 
1, 2, 3, 4 
Barbara 
Monsees 
St.Louis Med. 
Sch.- ACS 
Not Available 
3 
1, 2, 3, 4 
David G. 
Hoel 
Hollings Cancer 
Center- NIH 
Not Available 
3,4 
1, 2, 3, 4 
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Hearing # 8 
Presenter Organization  Organization Mission Presenter’s 
Interests 
Research  
Activities 
Funded 
Richard 
Klausner NCI 
The NCI, established under 
the National Cancer Institute 
Act of 1937, is the Federal 
Government's principal 
agency for cancer research and 
training 1,2, more 3,4 
1, 2, 3, 4 
James 
Marks CDC 
To promote health and quality 
of life by preventing and 
controlling disease, injury, and 
disability. 3, 4 
1, 2, 3, 4 
Nancy 
Brinker Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3,4 
1, 2, 3, 4 
Christine 
Carpenter 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  3,4 
1, 2, 3, 4 
Peri 
Giplin 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 3, 4 
N/A 
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breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  
Lasalle D. 
Leffall Susan G.Komen 
We are dedicated to curing 
breast cancer at every stage - 
from the causes to the cures, to 
the pain and anxiety of every 
moment in between. 3,4 
1, 2, 3, 4 
John 
Seffrin ACS 
The American Cancer Society 
is the nationwide community-
based voluntary health 
organization dedicated to 
eliminating cancer as a major 
health problem by preventing 
cancer, saving lives, and 
diminishing suffering from 
cancer, through research, 
education, advocacy, and 
service. 3, 4 
1, 2, 3, 4 
Fran 
Visco 
National Breast 
Cancer Coalition 
To achieve our mission of 
ending breast cancer, we focus 
on the following three main 
goals: RESEARCH: 
Increasing appropriations for 
high-quality, peer-reviewed 
research and working within 
the scientific community on 
issues of importance to 
women with, or at risk of, 
breast cancer ACCESS: 
Increasing access for all 
women to high-quality 
treatment and care, as well as 
breast cancer clinical trials 
INFLUENCE: Increasing the 
influence of women living 
with breast cancer and other 
breast cancer activists in the 
decision-making that impacts 
all issues surrounding breast 
cancer  3,4,5,6 
N/A 
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Based on this table the interest of the presenter reflects the advocacy coalition of 
the organization which the presenter represents.  The mission statement of each of these 
organizations reinforces the advocacy that the organization and/or presenter support and 
the research funding activities also reflect the mission and the coalition of the presenter 
and the organization. For example, Bernard Fisher of the NSABP Foundation, which 
supports the research for better medical treatments, testified for funding research 
activities that focus on Genetics, Screening Methods, and Medical Treatments during the 
Congressional hearings.  Which then lead to appropriations to NCI for funding these 
research activities and NCI provided grants to the NSABP Foundation for research 
activities which specifically deal with Genetics, Screening Methods and Medical 
Treatments.   
Most of the organizations which testified were organizations that receive funding 
for research from the NCI, other government agencies, and ACS. These organizations in 
turn testified in favor of the same research activities which lead to a reinforcing loop 
from the funding agencies to the researchers, who in turn testify in favor of the funding 
agencies and the continuation of the same or similar research activities. 
 Also, the majority of the presenter’s seem to provide testimony related to their 
individual interests or the interests of the organization they represented.  Though this type 
of testimony may help their continued research funding, it does pose a conflict of interest, 
because the presenters are biased by their own interests and not science.  These conflicts 
of interests are evident based on the presenter’s interests, the organization’s mission and 
the research activities funded.  
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The statistical analysis revealed that the average percent of lines of testimony by 
the presenters’ interests was not significant.  Therefore the “null hypothesis: the 
economic interests of the presenter do not impact the nature of the testimony” would be 
accepted and alternative hypothesis: “the economic interests of the presenter do impact 
the nature of the testimony” would be rejected. 
 
Summary 
 The combined use of qualitative and quantitative analysis provided both a specific 
and detailed view of the data and also allowed for an opportunity to adequately test each 
hypothesis.  Though the qualitative analysis suggested that all of the alternative 
hypotheses may be accepted, the quantitative analysis revealed that though there was a 
difference in testimony, this difference was not statistically significant for Hypotheses 1, 
2 and 3.  Table P-12 summarizes the quatantative analysis: 
 
Table P-12 
 
Item Test Statistic p Value Significance 
Gender Independent T-
Test 
t=  -0.534 0.594 No 
Education ANOVA F=0.168 0.973 No 
Hypothesis 1  Independent T-
Test 
t=  0.582 0.562 No 
Hypothesis 2 Independent T-
Test 
t=  1.75 0.082 No 
Hypothesis 3 Independent T-
Test 
t=  -0.136 0.892 No 
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CHAPTER 5: CONCLUSION 
Overview 
 Chapters one through four have provided an overview about the issues associated 
with the funding disparities between the actual causes of breast cancer and the research 
activities that are funded. The ground work for this study, including the research gaps and 
research objectives were outlined; along with the methodology to be used and the results 
from the research.  The purpose of this Chapter is to provide a summary of this study; 
present a discussion and potential conclusions from the results; identify the limitations of 
this study; and present the significance and future research implications of this study. 
Summary of the Study 
This study aimed to increase the understanding of how and why breast cancer 
research funding policies include or exclude funding for certain risk factors over others.  
The literature points to three specific triggers for breast cancer causation: genetics, life 
style choices, and multiple carcinogens in the environment.  Despite the existence of this 
literature which shows that 70% of breast cancer cases may be linked to the 
environmental carcinogens (Breast Cancer Action, 2006), there is little to no funding for 
research activities which focus on role of the environmental carcinogens on breast cancer 
incidence; this study was conducted to help determine how the research funds are being 
spent and why certain causes receive more research funding and other causes are not 
funded. 
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As mentioned in Chapter two the literature suggests that there seem to be two 
main discourses which attempt to explain how and why research funding policies for 
breast cancer research activities are determined.  The conventional discourse stems from 
the National Cancer Institute (NCI) and American Cancer Society (ACS).  This discourse 
explains that the research funding policies need to focus research activities around the 
first two risk factors, genetics and lifestyle choices, based on the following reasons: the 
increase in breast cancer can be attributed to women living longer and improved 
screening methods; medical treatments save lives and prevention techniques are not 
really available; it is difficult to impact the lifestyles of women; and it is difficult to study 
the effects of the environment and conclusively pinpoint how the environmental 
carcinogens cause breast cancer (NCI, 2006; ACS, 2006).    
The alternative discourse disagrees with these reasons and explains that the 
research funding policies systematically exclude funding for the role of environmental 
carcinogens because of the following reasons: the “ruling class” of agencies (the “Cancer 
Establishment” and “Cancer Industry”) which determine the research priorities are led by 
individuals with conflicts of interest; these conflicts of interest include companies that 
sponsor Breast Cancer Awareness month and who also own the chemical companies 
which produce herbicides that are linked to breast cancer incidence (Epstein & Steinmen, 
1997); powerful corporate actors, such as the pharmaceutical companies, promote 
research funding policies for medical treatment and exclude funding for the 
environmental causes because of  profit;  and that the existing research funding policies 
for new screening and medical treatments are more profitable than mitigation of 
environmental carcinogens which may lead to prevention (Moss, 2002). 
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The conventional and alternative discourses unite various agencies and actors to 
form six advocacy coalitions which compete during Congressional hearings to set 
research funding policies.  As mentioned earlier, the actors or agencies who represent 
these discourses share similar core beliefs about what the research funding policies for 
breast cancer should be.  These agencies are separated into the six coalitions, which 
represent the potential funding priorities based on the three causes which have been 
linked to breast cancer: genetics, life style choices, and environmental carcinogens.   
These six coalitions are: 
 Coalition A: Research into Genetics 
 Coalition B: Research into Lifestyle Choices 
 Coalition C: Research into Screening Methods 
 Coalition D: Research into Medical Treatments 
 Coalition E: Research into the Environment 
 Coalition F: Research into Prevention 
Coalitions A through D represent the “actors” or agencies who share core beliefs with the 
NCI and ACS forming the conventional discourse.  Coalitions E and F represent the 
alternative discourse and the agencies or actors who believe that research funding policies 
are influenced by power and profit. The theoretical framework suggested that certain 
causes received research funding over other causes and that funding decisions were based 
on power and economics and not science.  In order to best answer the above questions, 
three hypotheses were developed: 
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The first hypothesis for this study was that research funding policies for breast 
cancer are driven by a policy process that is dominated by a combination of 
discursive coalitions that marginalize advocacy for research on the 
environmental causes of breast cancer. 
The second hypothesis for this study was that the higher level of advocacy for 
non-environmental causes of breast cancer results in higher funding level for 
non-environmental causes of breast cancer over environmental causes. 
 The third hypothesis for this study was that the economic interests of the 
presenter impacts the nature if the testimony for or against research funding on 
the environmental causes of breast cancer. 
 
The Advocacy Coalition Framework was used as the theoretical model to better 
understand how different actors and agencies join together and form coalitions around 
these two main discourses and compete during the policy process to receive funding for 
research activities.  Since the research funding policy process involves testimony in front 
of Congress, Congressional hearings were coded to identify the dominant advocacy 
coalitions testifying and which of the two discourses (conventional or alternative) were 
supported during the hearings and to determine if there was marginalization of certain 
advocacy coalitions and hence the discourses they represented versus other advocacy 
coalitions and the discourse they represented.  
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Discussion and Conclusions 
A total of sixty-one testimonies were coded from eight Congressional hearings 
that were used in this study.  Fifty-three unique individuals testified during the hearings 
and the qualitative and quantitative analysis of the results revealed that representatives 
from NCI testified at all but one of the hearings and that the Susan G. Komen foundation 
had representatives testify at five of the eight hearings.  These results support the 
alternative discourse which states that the research funding priorities are set by the group 
of powerful organizations present during the research funding policy process.  The fact 
that the NCI testified at all of the hearings also supports Foucault’s notion of power and 
how knowledge and power combine to define the dominant discourse (Foucault, 1990, 
1995).   
In terms of breast cancer, the powerful (NCI and others, such as the Komen 
Foundation) testify and define the dominant discourse for the research activities should 
be funded for breast cancer research. Due to the fact that the actors from NCI and other 
agencies are in charge or in power their testimony which advocated for research activities 
dedicated to Screening Methods and Medical Treatments tends to form the dominant 
discourse for research funding activities for breast cancer. The actors from the NCI are 
also viewed as the scientific experts based on their titles and their affiliation with the 
NCI, so their testimony actually has more influence then may be the testimony from a 
survivor or a family member of a survivor. 
The role of power and the potential influence that patriarchy could have during 
the breast cancer research funding policy process was discussed in Chapter 2.  Women 
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were compared to the workers and how as the worker is excluded from participation in 
the policy process due to capitalism, women may be excluded from the breast cancer 
research funding policy process due to patriarchy (MacKinnon, 1982; Shelton and Agger, 
1993; Hartsock, 1998).  However, the results of this study showed that women testified at 
every hearing and in fact 54.7% of the people who testified at all of the hearings were 
women.  Which leads one to question why then the nature of testimony of the advocacy 
coalitions represented did not change.  This lack of change may be explained by the role 
of power; specifically Luke’s third level of power which involves shaping the view of 
individuals so that the view is reflective of those in power (Lukes, 1974).  This level of 
power implies that due to the fact that patriarchy is so institutionalized it influences the 
breast cancer research funding arena and it overshadows the gender of the presenter and 
the testimony is reflective of the patriarchic viewpoint about what research activities 
should be funded.   
The educational background of the presenter also coincided with the power and 
market system theories which support the notions of the Cancer Establishment and 
Cancer Industry.  Both of these notions point to the fact that those testifying have vested 
economic interests in the research funding policies; in fact the Cancer Establishment 
speaks to the idea that those in charge of the policies have conflicts of interests because 
they actually benefit from the funding decisions.   The Scientization of Politics also 
supports these two notions by explaining how political and moral decisions are 
determined by scientific experts and the public is excluded (Habermas, 1970: 62-80).  
The results of this research supported these notions and theories because more than half 
of the individuals testifying (67.9%) were scientific experts with either a medical degree 
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or a doctoral degree.  Their testimony was used to provide the technical evidence for 
research funding decisions and though survivors and family members of survivors 
testified, the activities funded for research did not change.  
 This lack of change in research activities funded and the powerful nature of the 
Cancer Establishment was further emphasized by the environmental hearing (hearing # 
4).  Twelve people testified during this hearing and they all represented the 
environmental advocacy coalition. This hearing was convened in 2001 to raise support 
for the establishment of the Breast Cancer and Environmental Research Act which would 
have created multidisciplinary research centers to study the role environmental 
carcinogens on breast cancer causation.  Both experts and survivors testified at the 
hearing and more than half of the presenters were women.  Despite the testimony, the Act 
never passed and no additional funds were allocated for research activities which 
specifically looked at the role of environmental causation on breast cancer.  This lack of 
change could have been due to the fact that the political make-up of the government 
changed around this time and that the political support for this act disappeared. 
  The other explanation for why this Act did not pass may have had to do with the 
Cancer Establishment and Cancer Industry and the fact that those in power have specific 
economic interests to continue funding research into Medical Treatments and Screening 
Methods.  This results support the fact that the role of the environmental carcinogens on 
breast cancer causation is marginalized because continued research into Medical 
Treatments and Screening Methods is economically beneficial to the current “ruling 
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class” which make the funding decisions and the research funding did not change despite 
the hearing. 
This marginalization of the environmental advocacy coalition raises questions 
about the impacts associated with environmental carcinogens and the disproportionate 
levels of exposure experienced by minority populations as outlined by the Environmental 
Justice (EJ) literature and associated health impacts (Bryant, 1995; Hofricter, 2000).  The 
EJ literature explains how minorities and low SES populations are disproportionately 
exposed to environmental carcinogens and that this same group is more likely to have 
limited access to health care.  Therefore by not increasing the funding for research into 
the environmental causes of breast cancer, minority women, who may have greater 
exposure to the environmental carcinogens and access to health care issues, may be more 
likely to get breast cancer and die from this disease.  Therefore, the lack of funding for 
research activities dedicated to the environmental carcinogens and breast cancer 
causation may be forming an unequal gradient of health care for minority and low SES 
populations. 
Overall, the coalitions advocating for Screening Methods and Medical Treatment 
provided the most testimony and continued to receive the majority of funding for 
research activities.  Despite the testimony advocating for research into the environmental 
causation and prevention, the actual funding for research activities did not change.  This 
lack of change in funding levels seems to support the alternative discourse and the 
notions of the Cancer Establishment and Cancer Industry.  The Cancer Establishment 
emphasizes that the current “ruling class” or power structure which consists of conflicts 
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of interests is driving the policy process and the Cancer Industry suggests that it is the 
economic interests driving the policy process. The theories of Power, Market System, and 
the Treadmill of Production as defined in Chapter 2 would apply based on the result of 
the lack of change in funding for research activities.   
These social theories predicted that the advocacy coalitions with the most lines of 
testimony would receive the most funding.  The advocacy coalitions with the greatest 
percent of lines of testimony were the Screening Methods and Medical Treatments and 
the majority of the research funding was also for these two coalitions; despite the fact that 
the majority of breast cancer cases can be attributed to environmental carcinogens.   
Figure P-8 depicts the causes, percent of lines of testimony and the actual funding 
levels for research activities. The data for the causes is from the NCI and the Breast 
Cancer Action, the data for the percent lines of testimony is from this research study, and 
the data for the research activities funded is from the NCI and ACS FY07 budget.  Based 
on the results and the available data for the causes of breast cancer, the percentage of 
testimony for each coalition and the research activities funded (depicted in Figure P-8), 
there is an obvious mismatch between the causes of breast cancer- 10 % genetics, 20% 
lifestyle choices, and the remaining 70% can be linked back to environmental 
carcinogens; the percentage lines of testimony- 38.16% Screening Methods, 32.24% 
Medical Treatments, 11.09% Environment, 7.74 % Prevention, 6.86% Lifestyle Choices, 
and 3.91% Genetics; and actual funding- 21% Medical Treatments, 20 % Genetics, 16% 
Screening Methods, 14% Lifestyle Choices, 9 % Prevention, and 3% Environment.  
Therefore, the current research activities do not address the actual cause of this disease 
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which would lead to decreases in the incidence rates of this disease, rather they continue 
to focus on research activities which only control mortality rates once the disease is 
discovered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure P-8: Funding Mismatch: Cause, Testimony, and Actual Research Activities Funded. 
 
 
 
Also, the fact that the funding level for research activities geared towards the role 
of environmental causation of breast cancer did not increase, despite the testimony 
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the funding being allocated towards research activities to address that cause.  Overall the 
research funding priorities seem to represent the discursive coalitions participating during 
the hearing process and the fact that the Environmental Advocacy Coalition did not have 
an impact on the funding levels for research activities geared towards the environmental 
causation of breast cancer, may be reflective of the unequal distribution of power 
amongst the different coalitions. 
In summary, this study was conducted to answer questions about research funding 
activities for breast cancer and to determine if and why there are funding disparities or a 
mismatch between the causes of breast cancer and the research activities which are 
funded.   The analysis of the results also revealed the following information: 
• All of the hearings did have testimony presented by women; though their 
testimony was based on their agency or organization affiliation and the 
discourse/coalition that the agency or organization supported. 
•  The coalitions for Screening Methods and Medical Treatments had the 
greatest amount of testimony during all of the hearings. 
• The Screening Methods and Medical Treatments coalitions also received 
the majority of the research funding. 
• Though there was an entire hearing devoted to the Environmental 
Advocacy Coalition and the role of the environmental carcinogens on 
breast cancer causation; no change was noticed in research funding for this 
coalition. 
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• Overall the research funding policies continued to fund research activities 
geared towards the first four coalitions: Genetics, Lifestyle Choices, 
Screening Methods, and Medical Treatments. 
• The last two coalitions: Environment and Prevention received minimal 
funding for research activities; despite the fact that the Environmental 
coalition had an entire hearing full of testimony about the environmental 
impact on breast cancer causation.    
Based on the analysis it may be concluded that there is a mismatch in research 
funding and that the policy process is driven by the alternative discourse and the 
conventional discourse.  The model below was originally presented in Chapter 2 and it 
represents the two discourses and the policy process for breast cancer.  The results of this 
study can conclude that the policy process for research funding activities for breast 
cancer is driven by Power and Profit, instead of Science. 
 
 
 
 
 
Limitations 
Congressional 
Hearing on 
Breast Cancer 
Issues: 
Testimony 
provided by 
experts 
 
Congressional 
Hearing Fiscal 
Year 
Appropriations 
 
Fiscal Budget for 
Research 
Activities: OMB, 
NCI, & ACS 
Money for 
research 
activities and 
data collected 
for future 
funding. 
Alternative Discourse: Power 
& Profit 
Conventional Discourse: Science 
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This study attempted to provide an accurate picture of the policy process for 
breast cancer research funding policies and how and why certain causes receive funding 
over other causes.  As with all research, several limitations were identified for this study.   
1. Actual Congressional hearings which encompass agents or actors can be 
complicated and often very dynamic. Thus, this study was limited by the narrative 
text provided as a written record of the hearings, which did not include the actual 
visual presentation that may have been provided by these agents and/or actors. 
2. The study is also limited by the reliance on US Government Printing Office to 
provide an accurate, written record of the hearings. 
3. There were only a limited number of hearings available for research funding 
policies for breast cancer. 
4.  Also, four assumptions were made:  
• the Congressional hearings used in the study were inclusive of breast 
cancer policy hearings; 
•  Congress invited all of the appropriate parties to testify at the hearings; 
• the ACF served as a good framework for this type of analysis;  
• and that the variables chosen for study will be adequate. 
Though two independent coders were used to validate the coding sheet, this study did 
have the potential limitations described above. 
 
 
   
 
120
Significance and Implications for Research and Policy 
 This research study provides two different levels of significance and implications 
for future research: theoretical and practical.  The theoretical significance of this work 
lies with utilizing the ACF and Congressional hearings to determine the role of 
environmental carcinogens on breast cancer causation.  Though the ACF has been 
utilized to analyze the policy process for other environmental policies, prior to this work 
it had not been used to analyze the role of environmental causation of a disease.  This 
work also contributed to the current body of literature for the use of the ACF and 
provided an example of how Congressional hearings may be used to show power 
dynamics during the policy process.   
 The future research implications from the theoretical significance of this work 
include: this work provides a specific approach on how to utilize the ACF to study policy 
processes for funding of research and public health activities and it provides a mechanism 
for integrating social theory and the environmental public health policy process to better 
understand the role of power and economics during policy development. 
The practical significance of this work is that it addressed the funding disparities 
for breast cancer and to shed light on how and why policies are determined and 
maintained.  This research study can be expanded to in the future to include other cancers 
and the associated research activities to determine if there are research funding 
disparities.  This research design can be replicated for other disease as well by identifying 
the major advocacy coalitions involved and conducting a content analysis of the 
appropriate policy documents.  
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